Plasma microRNA profiling for malaria disease: association with severity and P. falciparum 1

2 biomass

4

8

- Running Title: microRNA of severity and *P. falciparum* biomass 3
- Himanshu Gupta^{#±}, Mercedes Rubio[#], Antonio Sitoe, Rosauro Varo, Pau Cisteró, Lola Madrid, 5
- Inocencia Cuamba, Alfons Jimenez, Xavier Martiáñez-Vendrell, Diana Barrios, Lorena Pantano, 6
- 7 Allison Brimacombe, Mariona Bustamante, Quique Bassat^a, Alfredo Mayor^a
- Author affiliations: ISGlobal, Hospital Clínic, Universitat de Barcelona, Barcelona, Spain (H. 9
- 10 Gupta, M. Rubio, R. Varo, P. Cisteró, A. Jimenez, X. Martiáñez-Vendrell, D. Barrios, A.
- 11 Brimacombe, M. Bustamante, Q. Bassat, A. Mayor); Centro de Investigação em Saúde de Manhiça
- (CISM), Manhica, Mozambique (A. Sitoe, R. Varo, L. Madrid, I. Cuamba, O. Bassat, A. Mayor): 12
- Spanish Consortium for Research in Epidemiology and Public Health (CIBERESP), Madrid, Spain 13
- (A. Jimenez, M. Bustamante, O. Bassat, A. Mayor); Department of Biostatistics, Harvard T.H. 14
- Chan School of Public Health, Boston, MA, USA (L. Pantano); Universitat Pompeu Fabra (UPF), 15
- Barcelona, Spain (M. Bustamante); ICREA, Pg. Lluís Companys 23, 08010 Barcelona, Spain (Q. 16
- Bassat): Pediatric Infectious Diseases Unit, Pediatrics Department, Hospital Sant Joan de Déu 17
- 18 (University of Barcelona), Barcelona, Spain (Q. Bassat)
- [#]equal contribution 20

19

22

25

- ^aThese authors share senior authorship 21
- **Abstract word count: 148** 23
- **Text word count: 3485** 24

19th Dec

Address for correspondence: Dr. Himanshu Gupta, ISGlobal, Hospital Clínic, Universitat de Barcelona, Carrer Rosselló 153 (CEK Bldg), E-08036 Barcelona, Spain; E-mail: himanshu.gupta@isglobal.org; himanshugupta.hcu@gmail.com

19th Dec

Abstract

51

52 Severe malaria (SM) is a major public health problem in malaria-endemic countries. Sequestration 53 of *Plasmodium falciparum* (*Pf*) infected erythrocytes in vital organs and the associated 54 inflammation leads to organ dysfunction. MicroRNAs (miRNAs), which are rapidly released from 55 damaged tissues into the host fluids, constitute a promising biomarker for the prognosis of SM. This 56 57 study applied next-generation sequencing to evaluate the differential expression of miRNAs in SM compared to uncomplicated malaria (UM). Six miRNAs were associated with in vitro Pf 58 cytoadhesion, severity in Mozambican children and Pf biomass. Relative expression of hsa-miR-59 60 4497 quantified by TagMan-RT-qPCR, was higher in SM children plasmas compared to that of UM (p<0.048), and again correlated with Pf biomass (p=0.033). These findings suggest that different 61 physiopathological processes in SM and UM lead to differential expression of miRNAs and pave 62 63 the way to future studies aiming to assess the prognostic value of these miRNAs in malaria. 64 65 **Keywords:** miRNA, severe malaria, biomarkers, Next-generation sequencing, Histidine-rich 66 protein 2 67 68 69 70 71 72 73 74 75

Introduction

76

77

78

79

80

81

82

83

84

85

86

87

88

89

90

91

92

93

94

95

96

97

98

99

100

Case fatality rates for *Plasmodium falciparum* (*Pf*) severe malaria (SM) remain unacceptably high in young African children (1). Early detection and prompt treatment of SM are critical to improve the prognosis of sick children. Unfortunately, clinical signs and symptoms in many malaria patients, particularly at the beginning of the infection, may not adequately indicate the potential for the infection to trigger severe or life-threatening disease. Moreover, in malaria-endemic areas, where immunity to malaria is progressively acquired, the detection of peripheral Pf parasitemia in sick children does not necessarily prove that malaria is the cause of the severe pathology observed, given that many individuals may carry parasites without expressing clinical malarial disease (2). Sequestration of Pf infected erythrocytes (iEs) (3) in vital organs is believed to constitute a key pathogenic event leading to SM, as has been shown in post-mortem parasite counts in patients who died with cerebral malaria (CM) (4, 5). This extensive sequestration of parasitized erythrocytes in the microvasculature, together with the production of inflammatory mediators, leads to the dysfunction of one or more peripheral organs, such as the lungs (acute respiratory distress syndrome), kidneys (acute kidney injury) or brain (coma) (6, 7). This tissue-specific tropism of Pf parasites is mediated by the Pf erythrocyte membrane protein-1 (PfEMP1) which can bind to different host receptors on the capillary endothelium, uninfected erythrocytes and platelets (8, 9) such as endothelial receptor of protein C (ePCR), gC1qR, Intercellular adhesion molecule-1, CD36, chondroitin sulfate A or complement receptor 1 (10). Efforts have been made to identify biomarkers of SM which could be used for prevention of the severity of disease, and for early diagnosis (11). Several biomarkers related to endothelial activation and immune dysfunction have been associated with different malaria-derived severe pathologies

102

103

104

105

106

107

108

109

110

111

112

113

114

115

116

117

118

119

120

121

122

123

124

125

19th Dec Gupta et al

(11-14). Plasma levels of histidine-rich protein 2 (HRP2), a parasite-specific protein secreted by the parasite during its blood cycle, has been used as a biomarker of total parasite biomass (circulating and sequestered parasites) (15, 16) and therefore as a prognostic marker of the total parasite biomass and as a better proxy marker for SM than peripheral parasitemia (16). Organ damage and pathological disease states have also been associated with the rapid release of microRNAs (miRNAs) into the circulation, a class of endogenous small non-coding RNAs (18-24 nucleotides) (17). As secreted miRNAs can be detected in biological fluids such as plasma (18), they are currently being explored as promising non-invasive biomarkers to monitor organ functionality and tissue pathophysiological status. The content of miRNAs in the host is influenced by host-pathogen interactions (19). Sequestration of erythrocytes infected with *P. berghei* in mice brains has been demonstrated to modify the miRNA expression in cells (20). Similarly, sequestration of P. vivax gametocytes in the bone marrow has been associated with transcriptional changes of miRNAs involved in erythropoiesis (21). The aforementioned evidence suggests that *Plasmodium* parasites, although not able to produce miRNAs (22), could affect the production of organ-specific host miRNAs, pointing towards the potential of these small molecules to detect SM associated organ injury (23) and to confirm the contribution of malaria in the chain of events leading to death through the analysis of postmortem tissues (23). This study was conducted under the hypothesis that miRNA levels in plasma are differentially expressed among children with severe and uncomplicated malaria due to the parasite sequestration in vital organs of severely ill children. To identify promising biomarkers for SM, a small RNA next-generation sequencing (NGS) was applied to select miRNAs that were differentially expressed by human brain endothelial (HBE) cells exposed to Pf iEs selected for cytoadhesion to endothelial receptor of protein C, the main host receptor associated with SM (9), compared to those exposed to non-cytoadherent iEs, and non-infected erythrocytes (niEs), as well as by Mozambican children

127

128

129

130

131

132

133

134

135

136

137

138

139

140

141

142

143

144

145

146

147

148

149

Parasitological determinations

19th Dec Gupta et al

with SM compared to children with uncomplicated malaria (UM) (Figure 1). miRNAs that were differentially expressed in both analyses, together with the Pf biomass-associated miRNAs (correlation coefficient >0.50 (24)), were quantitatively confirmed in an independent validation cohort set of Mozambican children with SM and UM using TaqMan reverse transcriptase quantitative PCRs (RT-qPCRs). **Material and Methods Study population** Plasma samples used to assess miRNA levels were collected in two case-control studies conducted in Manhica District (southern Mozambique) during 2006 (N=113) and 2014 (N=91). Briefly, the cases were children under five years of age admitted to the Manhiça District Hospital with SM and controls were outpatient children with UM. Details on SM and UM criteria, case management, sample collection and storage, and laboratory blood analysis are included in the Technical Appendix. The study protocols for each of the two case-control studies from which this analysis was derived were approved by the National Mozambican Ethical Review Committee (Mozambique) and Hospital Clínic (Barcelona, Spain). A signed written informed consent was obtained from all participants' guardian or parent during the original studies.

Thick and thin blood films were prepared to quantify *Pf* parasitaemia. Approximately half of a 60μL dried blood drop on Whatman-903 filter paper was used to extract parasite DNA followed by a real-time quantitative PCR (qPCR) targeting the *Pf* 18S rRNA gene (25, 26). HRP2 levels were quantified using commercially available enzyme-linked immunosorbent assay (ELISA) kits and an in-house highly sensitive quantitative bead suspension array (qSA) based on Luminex technology (Technical Appendix).

Pf cytoadhesion assays

Cytoadhesion assays were performed to discover the differential expression of miRNAs. HBE cells were incubated with *Pf*-iEs at the trophozoite stage of the ePCR-binding FCR3 strain (ePCR-iE; which expresses the PfEPM1 protein that binds to ePCR receptor) and the 3D7 strain (3D7-iE; a strain without the protein that binds to ePCR receptor). Non-infected erythrocytes were used as negative control. Details on cytoadhesion assays are included in the Technical Appendix. The cell-conditioned media of each group were collected after 1hr (t1) and 24hrs of stimulation (t24) and subjected to RNA extraction followed by small-RNA sequencing.

Molecular procedures, gene target prediction and data analysis

RNA was extracted from cell-conditioned media (3ml) and plasma samples (1ml) using the miRNeasy tissues/cells kit and miRNeasy Plasma/Serum kit, respectively, with the use of 5µg UltraPureTM glycogen/sample. Given that the plasma samples were conserved in heparin, RNA was precipitated with LiCl as described elsewhere (27). Purified RNA was subjected to library preparation, pooling and sequencing using a HiSeq 2000 (Illumina) platform following the protocol for small RNAs (28), for more details see the Technical Appendix. A previously published pipeline

176

177

178

179

180

181

182

183

184

185

186

187

188

189

190

191

192

193

194

195

196

197

198

199

19th Dec Gupta et al

(28) was used to assess the sequencing quality, identification and quantification of small RNAs, normalization and other species RNA contamination (Technical Appendix). To detect miRNAs and isomiRs, reads were mapped to the precursors and annotated to miRNAs or isomiRs using miRBase version 21 with the miraligner (29). DESeq2 R package v.1.10.1 (R3.3.2) (30) was used to perform an internal normalization. Fifty µl of plasma from the Mozambican children (2014) with no haemolysis were used for RNA extraction as described above followed by RT-qPCR. Details on RT-qPCR and endogenous controls (ECs) are included in the Technical Appendix. miRNA relative expression levels (RELs) were calculated with the $2^{-\Delta Ct}$ method, where $\Delta Ct = [Ct \text{ (miRNA)} - \text{Mean Ct (ECs)}]$, considering efficiencies of 100% for all the miRNAs and ECs (31). The selected miRNAs were screened through different gene target prediction programs such as DIANA-microT-CDS, MiRDIP, MirGate, and TargetScan (Technical Appendix). Differential expression of miRNAs and isomiRs was assessed using DESEq2 and IsomiRs packages in R (29, 32), for more details see the Technical Appendix. All statistical analyses were performed using R3.3.2 and graphs were prepared with GraphPad (Technical Appendix).

201

202

203

204

205

206

207

208

209

210

211

212

213

214

215

216

217

218

219

220

221

222

223

224

19th Dec Gupta et al

Results Discovery phase miRNA expression by HBE cells The ePCR binding Pf strain (FCR3; ePCR-iE) showed higher levels of cytoadhesion to HBE cells (mean of 32.60 iE per 500cells, standard deviation [SD]:4.87) than a non-binding Pf (3D7; 3D7-iE) strain (3.20, SD:1.06; p=0.001) and non-infected erythrocytes (3.12, SD:0.39; p=0.001) (Appendix Figure 1). Three replicates of the media collected from each cytoadhesion assay after one (t1) and 24 hours (t24) were sequenced, giving a total of more than 200 million reads per lane, with a mean of 12.10 million reads (SD=13.31) per sample (Table 1; Figure 2A; Appendix Table 1). The mean percentage of miRNAs in the media samples analysed was 4.01% (SD=2.93) and a mean of 203 (SD=93.82) distinct miRNAs (a minimum of 101 and a maximum of 465) were detected (Appendix Table 1). The ten most expressed miRNAs for all samples at t1 and t24 time points are described in Figure 2B. No contamination with RNA from other species was observed. One hour after incubating the HBE cells with Pf infected and non-infected erythrocytes, 111 miRNAs were found to be differentially expressed in cell-condition media of niE and ePCR-iE, 76 of them being downregulated and 35 upregulated in ePCR-iE compared to niE (Figure 2C; Appendix Table 2). At this same time point, 100 miRNAs were differentially expressed in cellcondition media of 3D7-iE and ePCR-iE, 67 were downregulated and 33 upregulated in ePCR-iE compared to 3D7-iE (Figure 2D; Appendix Table 3). Overall, 89 miRNAs were differentially expressed in ePCR-iE compared to both niE and 3D7-iE, 28 and 61 of which were upregulated and downregulated, respectively, in ePCR-iE. There were no differentially expressed miRNAs between

19th Dec

225

226

227

228

229

230

231

232

233

234

235

236

237

238

239

240

241

242

243

244

245

246

247

248

niE and 3D7-iE cell-condition media. At t24, only hsa-miR-451a was significantly upregulated in cell-condition media of ePCR-iE with respect to niE and 3D7-iE. There were no significantly different miRNAs found between niE and 3D7-iE cell-condition media. All differentially expressed isomiRs were from the selected miRNAs and none of them presented any modifications in the seed region. miRNAs expression in plasmas from Mozambican children with malaria of varying severity Out of 113 plasma samples collected from Mozambican children with SM (N=57) and UM (N=56) in 2006, 11 samples were discarded because of haemolysis (N=5; OD₄₁₄>0.2) (33), and because no peak was observed between 133-150 nucleotides (typical size for miRNAs plus library adaptors) on the bioanalyzer results after library preparation (N=6). Among the 102 sequenced samples (SM=53: UM=49), 19 samples (9 SM; 10 UM) were further excluded because of the low number of miRNA reads (<10,000 reads). Finally, samples from 83 children (44 with SM and 39 with UM) were included in the analysis (Table 2). The characteristics of Mozambican children are presented in Table 2. The sequencing of the 83 plasma samples yielded a mean of 9.42 million reads (SD=6.4) per sample (Figure 2A; Table 1; and Appendix Table 4). The mean percentage of miRNAs per plasma samples was 20.5% (SD=13.2), with a mean of 395 (SD=169) distinct miRNAs detected (a minimum of 116 and a maximum of 786; Appendix Table 4). The total number of miRNAs detected across samples was 1450. The ten most expressed miRNAs can be found in Figure 2B. No contamination with RNA from other species was observed.

hsa-miR-122-5p was found upregulated in children with SM (Table 3). In the sub-analysis by signs of severity, five miRNAs were found associated with SA, prostration and ARD (Table 3). Twelve miRNAs were found associated with PM-agglutination and cytoadhesion to g1CqR (Table 3). No associations were observed between miRNA counts and rosetting, CD36 and CD54. After adjusting for multiple comparisons, three (hsa-miR-10b-5p, hsa-miR-378a-3p and hsa-miR-4497) out of the 1450 miRNAs (identified in RNA sequencing data) were found to correlate with HRP2 levels determined by qSA (Spearman analysis; Figure 3). Similar correlations were observed when HRP2 levels were determined by ELISA (Appendix Table 5). miRNAs were neither associated with hepatomegaly nor with splenomegaly. All differentially expressed isomiRs between children with SM and UM belong to the differentially expressed miRNAs, with no modifications in the seed region.

Validation cohort

Among the 89 miRNAs differentially expressed in cell-condition media of HBE cells exposed to niE and 3D7-iE compared to ePCR-iE, 5 miRNAs were further confirmed to be differentially expressed between children with SM and UM. These five miRNAs (hsa-miR-122-5p, hsa-miR-320a, hsa-miR-1246, hsa-miR-1290 and hsa-miR-3158-3p) along with hsa-miR-4497 miRNA, which had a correlation coefficient with HRP2 higher than 0.5 (Figure 3), were selected for TaqMan-RT-qPCRs validation in an independent cohort of children with SM and UM recruited in 2014. Among the 91 plasma samples collected from these children, 21 were discarded because of haemolysis (OD₄₁₄>0.2) (33). Out of the 70 remaining samples, 40 and 30 samples were collected from children with SM and UM, respectively (Table 2). The characteristics of Mozambican children are presented in Table 2.

All samples tested by RT-qPCR amplified the exogenous control (ath-miR-159a) with a Ct value<18 and a coefficient of variance (CV) <5%, suggesting the correct RNA extraction and cDNA preparation. hsa-miR-191-5p (CV=4.8%, basemean=3953.3, log₂fold change (FC)=-0.02 and SD=0.56), hsa-miR-30d-5p (CV=4.9%, basemean=14172.31, FC=0.01 and SD=0.61) and hsa-miR-148a-3p (CV=5%, basemean=111593.08, FC=0.11 and SD=0.82) were selected as a panel of ECs for RT-qPCR analysis. Among these three, the NormFinder stability value was 0.044 for the combination of hsa-miR-30d-5p and hsa-miR-191-5p, and were thus selected as ECs. No statistically significant differences were found when Ct values of exogenous and two endogenous controls were compared between SM and UM samples (Appendix Figure 2). Standard curves for all miRNAs (ECs and selected miRNAs) were performed, giving efficiencies between 91.1% - 103.8% (Appendix Table 6), which were assumed as 100% to calculate the relative expression values using the $2^{-\Delta Ct}$ method (31). The relative expression levels of hsa-miR-3158-3p and hsa-miR-4497 were significantly higher in children with SM than UM (p<0.05) as shown in Figure 4. hsa-miR-3158-3p levels were higher in children with prostration, multiple seizures and ARD compared to UM (p<0.05; Figure 5). Severe anaemia and ARD symptoms were associated with higher hsa-miR-4497 levels (p<0.05; Figure 5). No such associations were observed for CM and hypoglycaemia. RELs of hsa-miR-3158-3p and hsa-miR-4497 were found positively correlated with HRP2 levels quantified by qSA (p<0.05; Figure 6), with similar correlations observed when HRP2 levels were determined by ELISA

miRNA gene target prediction

(Appendix Table 5).

19th Dec

274

275

276

277

278

279

280

281

282

283

284

285

286

287

288

289

290

291

292

293

294

295

296

297

A total of 87 putative targets for hsa-miR-3158-3p and hsa-miR-4497 miRNAs were identified, none of which were shared by both miRNAs (Appendix Table 7). Forty-five experimentally validated mRNA targets were predicted for hsa-miR-3158-3p and 42 for hsa-miR-4497. The predicted targets were found to be involved in a broad range of biological processes (Appendix Table 8). However, significance was lost when adjusted by the Benjamini-Hochberg method. None of the target genes were clustered under the KEGG pathway with p value <0.05.

Discussion

As microRNAs can reflect disease states and organ damage due to their specificity to cell type (17), they have the potential to provide a new screening method for early detection of pathological *Pf* sequestration and may consequently become an effective prognosis tool for severe malaria. Moreover, the detection of miRNAs associated with organ damage in host biofluids may provide an alternative to post-mortem autopsies for determining the presence of parasites in host vital organs. This approach creates new opportunities to develop malaria diagnostic tools that can guide treatment decisions, and to understand the role of human miRNAs in several disease conditions (23).

In the discovery phase, 89 miRNAs were found to be differentially expressed in the media of HBE cells after incubation with an ePCR-cytoadherent *Pf* strain as compared with non-cytoadherent parasites and non-infected erythrocytes. In addition, fifteen miRNAs in plasma samples obtained from Mozambican children were associated with SM, with specific severity symptoms, and with the cytoadherent *Pf* phenotype, compared to UM and non-cytoadherent parasites. In the validation

phase, the higher abundance of hsa-miR-3158-3p and hsa-miR-4497 in SM children compared to

children with UM was further confirmed. Prostration, multiple seizures, SA and ARD symptoms of

19th Dec

323

324

325

326

327

328

329

330

331

332

333

334

335

336

337

338

339

340

341

342

343

344

345

346

347

severity were associated with higher levels of hsa-miR-3158-3p and hsa-miR-4497. hsa-miR-4497 levels were also positively correlated with the parasite biomass as quantified by the levels of HRP2 both in the discovery and validation phases. Overall, these findings suggest that different physiopathological processes in SM and UM lead to differential expression of miRNAs in plasma. HBE cells released a high number of the miRNAs when they were stimulated with an ePCRbinding Pf strain within the first hour of incubation. After 24 hours the system stabilizes and only one miRNA (hsa-miR-451a) was found at higher levels in cell-conditioned media of HBE cells incubated with an ePCR-binding strain compared to cells stimulated with non-adherent (3D7-iE) or non-infected erythrocytes. miR-451 has been implicated in translocation to form a chimera with Plasmodium mRNAs to block their translation (34), and also found to be abundant in sickle erythrocytes (35). In addition, it was shown that parasites could reduce miR-451 levels in host fluids (36). However, it was not confirmed in plasmas from Mozambican children in this study. Five miRNA levels were higher in children with SM and severity symptoms (prostration, SA and ARD) compared to UM cases. Pf cytoadhesion phenotypes (PM-agglutination and cytoadhesion to gClqR) were also associated with the differential expression of miRNAs, suggesting that the interaction between PfEMP1 and host receptors leads to the secretion to plasma of specific miRNAs. Moreover, three miRNAs (hsa-miR-10b-5p, hsa-miR-378a-3p and hsa-miR-4497) were positively correlated with HRP2 levels. Six candidate miRNAs that were identified in the discovery phase were selected to determine the validity of the previous results in an independent cohort of Mozambican children. The relative expression of hsa-miR-3158-3p and hsa-miR-4497 was significantly higher in children with SM compared to UM, with hsa-miR-3158-3p levels being higher in children with prostration, multiple seizures as well as ARD, and hsa-miR-4497 in children with SA and ARD. To our knowledge, hsa-

349

350

351

352

353

354

355

356

357

358

359

360

361

362

363

364

365

366

367

368

369

370

371

372

19th Dec Gupta et al

miR-3158-3p, which is widely expressed in skin, spleen, kidney and brain tissues (37), has been associated with bipolar disorders (38), but not with other infectious diseases. Further validation is required for hsa-miR-3158-3p, as the levels of this miRNA were found to be downregulated in the plasma from Mozambican children recruited in 2006 with positive PM-agglutination compared to no PM-agglutination, a Pf cytoadhesion phenotype which has been associated with malaria severity (39). However, the positive correlation of hsa-miR-4497 with HRP2 levels, which was consistently observed in the cohort of children from 2006 and 2014, suggesting that increasing parasite biomass associated with parasite sequestration may lead to higher levels of secretion of this specific miRNA by damaged tissues. hsa-miR-4497 is widely expressed in the lymph nodes, spleen, kidney and liver tissues (37). Overall, this study shows that hsa-miR-4497, which is also associated with SM, might be an interesting proxy marker of malaria severity. However, hsa-miR-4497 was found as a tumour suppressor (40), and associated with *Mycobacterium tuberculosis* infection (41). Therefore, longitudinal studies are required to assess the prognostic value of this miRNA, as well as to estimate its differential expression in children with severity due to non-malarial infections. Few of the most expressed miRNAs found in the present study, which represent a 70% of the total miRNA counts in plasma samples, have been reported as highly abundant in plasma samples previously (28, 42). According to public data deposited in the miRmine database (43), hsa-miR-486-5p and hsa-miR-451a are the two most abundant miRNAs in plasma and were also present in the list of ten most expressed miRNAs of this study. Although there is no data available on miRNAs from cell-conditioned media of HBE cells, miRNA data from other cell types, such as primary tissue explants, primary stromal cells and breast cancer cell lines, also show low miRNA vield (44), similar to this study. This observation indicates that RNA sequencing data obtained in this study is of good quality and can be used for posterior analysis with high confidence. However, this study has several limitations. First, only HBE cells and ePCR-binding parasites were utilized

374

375

376

377

378

379

380

381

382

383

384

385

386

387

388

389

390

391

392

393

394

395

396

397

19th Dec Gupta et al

for the *in vitro* assay, and therefore miRNAs produced by other parasite-host interactions contributing to SM may have been missed. Second, plasma samples used in this study were collected retrospectively. Therefore, factors prior to small RNA sequencing and TagMan-RTqPCRs, such as time taken between centrifugation, storage, and storage temperature, might have varied among the samples, affecting miRNA plasma levels (45, 46). However, confirmation of findings in both the study cohorts suggest a minimal impact of pre-analytical conditions in the results. Third, variations in the number of miRNAs identified in replicates of *in vitro* experiments may have led to the loss of some miRNAs. Fourth, the lack of tissue samples from organs with Pf sequestration restricted the histological confirmation of identified miRNAs, and the presence of coinfections other than blood culture positive bacteraemia cannot be neglected in the studied plasma samples. Finally, the association of each miRNA with specific symptoms that are part of the SM case definition may need further validation using a larger sample size, considering that our numbers were relatively small for individual SM criteria. In addition, future studies using the machinelearning approaches would allow the identification of a combination of miRNAs that may detect SM pathologies. In conclusion, the profiling of miRNAs in media from HBE cells after incubation with a cytoadherent Pf strain and in plasmas from Mozambican children with different clinical presentations allowed the identification of promising miRNA candidates for characterizing severe malaria, specifically hsa-miR-4497. This study opens the ground for future analyses to understand the value of these miRNAs as a prognostic biomarker and for disentangling the aetiology of severe malaria.

399

400

401

402

403

404

405

406

407

408

409

410

411

412

413

414

415

416

417

418

419

420

421

422

Acknowledgements

19th Dec Gupta et al

We are grateful to the children who participated in the study; the staff of the Manhiça District Hospital; the clinical officers, field supervisors and data managers; G. Cabrera, L. Mussacate, N. Ernesto José and A. Nhabomba for their contribution to the collection of parasites; L. Puyol for her laboratory management, as well as everyone who supported this study directly or indirectly. We also thank Ruhi Sikka, Varun Sharma, Rebecca Smith-Aguasca, Malia Skjefte, and Catriona Patterson for their useful comments on this manuscript. [±]HG moved to the department of Infection Biology, London School of Hygiene and Tropical Medicine, London, UK. This work was supported by the Instituto de Salud Carlos III (PI13/01478 cofunded by the Fondo Europeo de Desarrollo Regional [FEDER], CES10/021-I3SNS to AM and CP11/00269 from the Miguel Servet program to QB). HG was supported (Jan/2017 – Jan/2019) by the Science and Engineering Research Board (SERB), Department of Science & Technology, Government of India (Overseas Postdoctoral Fellowship, SB/OS/PDF-043/2015-16), ISGlobal is a member of the CERCA Programme, Generalitat de Catalunya (http://cerca.cat/en/suma/). CISM is supported by the Government of Mozambique and the Spanish Agency for International Development (AECID). This research is part of ISGlobal's Program on the Molecular Mechanisms of Malaria, which is partially supported by the Fundación Ramón Areces.

424

425

426

427

428

429

430

431

432

433

434

435

436

437

438

439

440

441

442

443

444

445

446

447

19th Dec Gupta et al

Biographical Sketch Dr. Gupta is a molecular biologist and an early career malaria disease researcher. His research focuses on host and parasite factors associated with severe malaria, and on the use of molecular tools for the active surveillance of emerging drug resistance, gene deletions, and afebrile malaria in malaria-endemic regions. Availability of data and materials The datasets analysed in this study are available from the corresponding author on request. **Competing interests** The authors declare that they have no competing interests. **Authors' contributions** HG, MR carried out the molecular analysis, results interpretation and wrote the first draft of this manuscript. PC also carried out molecular analysis and conducted cytoadhesion assays. AS, RV, LM and IC participated in fieldwork, collected clinical, epidemiological data, plasma samples, dried blood drop filter papers and performed microscopy. AJ, XMV and DB participated in HRP2 analyse. MR, PC, HG, LP, AB and MB participated in bioinformatics and statistical analyses. QB and AM participated in the study design, supervision, funding acquisition, project administration and coordinated all the stages of the project. All authors reviewed and approved the final manuscript.

References

448

449

- Dondorp AM, Fanello CI, Hendriksen IC, Gomes E, Seni A, Chhaganlal KD, et al. 1. 450
- Artesunate versus quinine in the treatment of severe falciparum malaria in African children 451
- (AOUAMAT): an open-label, randomised trial. Lancet. 2010 Nov 13:376(9753):1647-57. 452
- Gravenor MB, van Hensbroek MB, Kwiatkowski D. Estimating sequestered parasite 453 2.
- population dynamics in cerebral malaria. Proc Natl Acad Sci U S A. 1998 Jun 23;95(13):7620-4. 454
- Miller LH, Baruch DI, Marsh K, Doumbo OK. The pathogenic basis of malaria. Nature. 455 2002 Feb 7;415(6872):673-9. 456
- Dorovini-Zis K, Schmidt K, Huynh H, Fu W, Whitten RO, Milner D, et al. The 457
- neuropathology of fatal cerebral malaria in malawian children. Am J Pathol. 2011 458
- May;178(5):2146-58. 459
- Nagatake T, Hoang VT, Tegoshi T, Rabbege J, Ann TK, Aikawa M. Pathology of 460
- falciparum malaria in Vietnam. Am J Trop Med Hyg. 1992 Aug;47(2):259-64. 461
- Milner DA, Jr., Whitten RO, Kamiza S, Carr R, Liomba G, Dzamalala C, et al. The systemic 462
- pathology of cerebral malaria in African children. Frontiers in cellular and infection microbiology. 463
- 2014;4:104. 464
- White NJ, Turner GD, Day NP, Dondorp AM. Lethal malaria: Marchiafava and Bignami 465 7.
- 466 were right. The Journal of infectious diseases. 2013 Jul 15;208(2):192-8.
- Rowe JA, Claessens A, Corrigan RA, Arman M. Adhesion of Plasmodium falciparum-467
- infected erythrocytes to human cells: molecular mechanisms and therapeutic implications. Expert 468
- reviews in molecular medicine. 2009 May 26;11:e16. 469
- Turner L, Lavstsen T, Berger SS, Wang CW, Petersen JE, Avril M, et al. Severe malaria is 470
- associated with parasite binding to endothelial protein C receptor. Nature. 2013 Jun 471
- 472 27:498(7455):502-5.
- Jensen AR, Adams Y, Hviid L. Cerebral Plasmodium falciparum malaria: The role of 473
- PfEMP1 in its pathogenesis and immunity, and PfEMP1-based vaccines to prevent it. Immunol 474
- Rev. 2020 Jan;293(1):230-52. 475
- Sahu PK, Satpathi S, Behera PK, Mishra SK, Mohanty S, Wassmer SC. Pathogenesis of 476
- 477 cerebral malaria: new diagnostic tools, biomarkers, and therapeutic approaches. Frontiers in cellular
- and infection microbiology. 2015:5:75. 478
- Erdman LK, Petes C, Lu Z, Dhabangi A, Musoke C, Cserti-Gazdewich CM, et al. Chitinase 479 12.
- 480 3-like 1 is induced by Plasmodium falciparum malaria and predicts outcome of cerebral malaria and
- severe malarial anaemia in a case-control study of African children. Malaria journal. 2014 Jul 481
- 482 21;13:279.
- Lucchi NW, Jain V, Wilson NO, Singh N, Udhayakumar V, Stiles JK. Potential serological 483 13.
- biomarkers of cerebral malaria. Disease markers. 2011;31(6):327-35. 484
- Tahar R, Albergaria C, Zeghidour N, Ngane VF, Basco LK, Roussilhon C. Plasma levels of 485
- 486 eight different mediators and their potential as biomarkers of various clinical malaria conditions in
- African children. Malaria journal. 2016 Jun 29:15:337. 487
- Dondorp AM, Desakorn V, Pongtavornpinyo W, Sahassananda D, Silamut K, Chotivanich 488
- 489 K, et al. Estimation of the total parasite biomass in acute falciparum malaria from plasma PfHRP2.
- 490 PLoS medicine. 2005 Aug;2(8):e204.
- Hendriksen IC, Mwanga-Amumpaire J, von Seidlein L, Mtove G, White LJ, Olaosebikan R, 491
- et al. Diagnosing severe falciparum malaria in parasitaemic African children: a prospective 492
- evaluation of plasma PfHRP2 measurement. PLoS medicine. 2012;9(8):e1001297. 493

- Cortez MA, Bueso-Ramos C, Ferdin J, Lopez-Berestein G, Sood AK, Calin GA. 494
- 495 MicroRNAs in body fluids--the mix of hormones and biomarkers. Nat Rev Clin Oncol. 2011
- Aug:8(8):467-77. 496
- Mitchell PS, Parkin RK, Kroh EM, Fritz BR, Wyman SK, Pogosova-Agadjanyan EL, et al. 497
- Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci U S 498
- 499 A. 2008 Jul 29;105(30):10513-8.
- 500 Hakimi MA, Cannella D. Apicomplexan parasites and subversion of the host cell microRNA
- pathway. Trends in parasitology. 2011 Nov;27(11):481-6. 501
- 502 El-Assaad F, Hempel C, Combes V, Mitchell AJ, Ball HJ, Kurtzhals JA, et al. Differential
- 503 microRNA expression in experimental cerebral and noncerebral malaria. Infect Immun. 2011
- 504 Jun;79(6):2379-84.
- Baro B, Deroost K, Raiol T, Brito M, Almeida AC, de Menezes-Neto A, et al. Plasmodium 505
- vivax gametocytes in the bone marrow of an acute malaria patient and changes in the erythroid 506
- miRNA profile. PLoS neglected tropical diseases. 2017 Apr;11(4):e0005365. 507
- Xue X, Zhang O, Huang Y, Feng L, Pan W. No miRNA were found in Plasmodium and the 508
- 509 ones identified in erythrocytes could not be correlated with infection. Malaria journal. 2008 Mar 510 10;7:47.
- Rubio M, Bassat Q, Estivill X, Mayor A. Tying malaria and microRNAs: from the biology 511 23.
- 512 to future diagnostic perspectives. Malaria journal. 2016 Mar 15;15:167.
- Available 513 Spearman's correlation. [cited: from:
- 514 http://www.statstutor.ac.uk/resources/uploaded/spearmans.pdf
- 515 Mayor A, Serra-Casas E, Bardaji A, Sanz S, Puyol L, Cistero P, et al. Sub-microscopic
- infections and long-term recrudescence of Plasmodium falciparum in Mozambican pregnant 516
- women. Malar J. 2009 Jan 9;8:9. 517
- Taylor SM, Mayor A, Mombo-Ngoma G, Kenguele HM, Ouedraogo S, Ndam NT, et al. A 518
- quality control program within a clinical trial Consortium for PCR protocols to detect Plasmodium 519
- species. Journal of clinical microbiology. 2014 Jun;52(6):2144-9. 520
- Wang J, Chen J, Chang P, LeBlanc A, Li D, Abbruzzesse JL, et al. MicroRNAs in plasma of 521
- pancreatic ductal adenocarcinoma patients as novel blood-based biomarkers of disease. Cancer 522
- prevention research. 2009 Sep;2(9):807-13. 523
- Rubio M, Bustamante M, Hernandez-Ferrer C, Fernandez-Orth D, Pantano L, Sarria Y, et al. 524
- 525 Circulating miRNAs, isomiRs and small RNA clusters in human plasma and breast milk. PLoS
- One. 2018:13(3):e0193527. 526
- Pantano L, Estivill X, Marti E. SeqBuster, a bioinformatic tool for the processing and 527 29.
- 528 analysis of small RNAs datasets, reveals ubiquitous miRNA modifications in human embryonic
- 529 cells. Nucleic acids research. 2010 Mar;38(5):e34.
- Love MI, Huber W, Anders S. Moderated estimation of fold change and dispersion for 530
- 531 RNA-seg data with DESeg2. Genome biology. 2014;15(12):550.
- Marabita F, de Candia P, Torri A, Tegner J, Abrignani S, Rossi RL. Normalization of 532
- circulating microRNA expression data obtained by quantitative real-time RT-PCR. Briefings in 533
- 534 bioinformatics. 2016 Mar;17(2):204-12.
- 32. Pantano L, Estivill X, Marti E. A non-biased framework for the annotation and classification 535
- of the non-miRNA small RNA transcriptome. Bioinformatics. 2011 Nov 15;27(22):3202-3. 536
- 537 Kirschner MB, Edelman JJ, Kao SC, Vallely MP, van Zandwijk N, Reid G. The Impact of
- Hemolysis on Cell-Free microRNA Biomarkers. Frontiers in genetics. 2013;4:94. 538
- 539 LaMonte G, Philip N, Reardon J, Lacsina JR, Majoros W, Chapman L, et al. Translocation
- of sickle cell erythrocyte microRNAs into Plasmodium falciparum inhibits parasite translation and 540
- contributes to malaria resistance. Cell host & microbe. 2012 Aug 16;12(2):187-99. 541

- Chen SY, Wang Y, Telen MJ, Chi JT. The genomic analysis of erythrocyte microRNA 542
- 543 expression in sickle cell diseases. PLoS One. 2008 Jun 4;3(6):e2360.
- Rathien T, Nicol C, McConkey G, Dalmay T. Analysis of short RNAs in the malaria 544 36.
- parasite and its red blood cell host. FEBS Lett. 2006 Oct 2;580(22):5185-8. 545
- Ludwig N, Leidinger P, Becker K, Backes C, Fehlmann T, Pallasch C, et al. Distribution of 546
- 547 miRNA expression across human tissues. Nucleic acids research. 2016 May 5;44(8):3865-77.
- Maffioletti E, Cattaneo A, Rosso G, Maina G, Mai C, Gennarelli M, et al. Peripheral whole 548
- blood microRNA alterations in major depression and bipolar disorder. Journal of affective 549
- disorders. 2016 Aug;200:250-8. 550
- Mayor A, Hafiz A, Bassat O, Rovira-Vallbona E, Sanz S, Machevo S, et al. Association of 551
- 552 severe malaria outcomes with platelet-mediated clumping and adhesion to a novel host receptor.
- PLoS One. 2011 Apr 29;6(4):e19422. 553
- Chen X, Zhang L, Tang S. MicroRNA-4497 functions as a tumor suppressor in laryngeal 554
- squamous cell carcinoma via negatively modulation the GBX2. Auris Nasus Larynx. 2019 555
- Feb:46(1):106-13. 556
- 557 41. Das K, Saikolappan S, Dhandayuthapani S. Differential expression of miRNAs by
- macrophages infected with virulent and avirulent Mycobacterium tuberculosis. Tuberculosis. 2013 558
- 559 Dec:93 Suppl:S47-50.
- 560 42. Tonge DP, Gant TW. What is normal? Next generation sequencing-driven analysis of the
- human circulating miRNAOme. BMC molecular biology. 2016 Feb 9;17:4. 561
- 562 43. Panwar B, Omenn GS, Guan Y. miRmine: a database of human miRNA expression profiles.
- 563 Bioinformatics. 2017 May 15;33(10):1554-60.
- Glynn CL, Khan S, Kerin MJ, Dwyer RM. Isolation of secreted microRNAs (miRNAs) from 564
- cell-conditioned media. MicroRNA. 2013;2(1):14-9. 565
- Glinge C, Clauss S, Boddum K, Jabbari R, Jabbari J, Risgaard B, et al. Stability of 566
- Circulating Blood-Based MicroRNAs Pre-Analytic Methodological Considerations. PLoS One. 567
- 2017;12(2):e0167969. 568

572

573

574

575

576

577

578

579

580

- Sourvinou IS, Markou A, Lianidou ES. Quantification of circulating miRNAs in plasma: 569
- effect of preanalytical and analytical parameters on their isolation and stability. The Journal of 570
- molecular diagnostics: JMD. 2013 Nov;15(6):827-34. 571

Figure 1: Schematic representation of the study design to identify miRNA based biomarkers of severe malaria. [ePCR: endothelial protein-C receptor (a binding *P. falciparum* strain-FCR3); 3D7: a non-binding *P. falciparum* strain; iE: infected erythrocyte; niE: non-infected erythrocyte; HRP2: Histidine-rich protein 2].




Figure 2: RNA sequencing of human brain endothelial (HBE) cell media and plasma from Mozambican children recruited in 2006.

596

597

598

599

600

601

602

603

604

605

606

607

608

609

A) Percentage of mapped reads in different species of small RNAs, for both in vitro and ex vivo approaches. **B**) Ten most expressed miRNAs in HBE cell medias and plasmas. Colour coded cells show the percentage of each assay/condition (columns) for each miRNA (rows). Volcano plot of differentially expressed miRNAs in C) cell-condition media of non-infected erythrocytes (niE) versus cell-condition media of infected erythrocytes with the FCR3-ePCR strain (ePCR-iE) incubated with HBE cells and **D**) cell-condition media of infected erythrocytes with 3D7 strain (3D7-iE) versus cell-condition media of infected erythrocytes with the FCR3-ePCR strain (ePCRiE) incubated with HBE cells. Both comparisons (C and D) were adjusted for multiple testing by the Benjamini-Hochberg method. Negative log2FoldChanges indicates overexpression in ePCR-iE samples. (SM: severe malaria; UM: uncomplicated malaria).






Figure 3: Spearman correlations between HRP2 levels and miRNA relative expression levels

(RELs) in plasma samples from Mozambican children recruited in 2006.

HRP2 levels and miRNA RELs were log transformed. The correlation analysis was adjusted for multiple testing by the Benjamini-Hochberg method.



19th Dec






Figure 4: miRNA validation in plasma samples of Mozambican children recruited in 2014.

19th Dec

Relative expression levels (RELs) were calculated with respect to the mean of two endogenous controls (hsa-miR-30d-5p and hsa-miR-191-5p) and compared between children with severe malaria (SM) and uncomplicated malaria (UM). Statistical differences were obtained from Mann-Whitney U test. T bars represent median and Interquartile Ranges (IQR).




Figure 5: Association of miRNA levels with symptoms of severity.

19th Dec

644

645

646

647

648

649

650

651

652

653


654

655

656

657

Relative expression levels (RELs) were calculated with respect to the mean of two endogenous controls (hsa-miR-30d-5p and hsa-miR-191-5p) and compared between children with uncomplicated malaria (UM) and symptoms of severity. Distributions were compared using Mann-Whitney U test. T bars represent median and Interquartile Ranges (IQR). P values are shown for significant comparisons. [Prostration (P), Multiple seizures (MS), Acidosis or acute respiratory distress (ARD), Severe anaemia (SA)].



19th Dec

Figure 6: Spearman correlations between HRP2 levels and miRNA relative expression levels (RELs) in plasma samples from Mozambican children recruited in 2014. HRP2 levels and miRNA RELs were log transformed.




Table 1: Quality control and mapped reads (mean and standard deviations) in different species of small RNAs obtained from cell-conditioned media of human brain endothelial cells exposed to cytoadherent P. falciparum infected and non-infected erythrocytes, and plasma of Mozambican children with severe and uncomplicated malaria.

		Condition niE 3D7-iE ePCR-iE UM SM							
		niE 3D7-iE			ePCR-iE		SM		
		t1 (N=3)	t24 (N=3)	t1 (N=3)	t24 (N=3)	t1 (N=3)	t24 (N=3)	(N=39)	(N=44)
Total reads, millions (SD)		8.70 (3.55)	16.71 (14.59)	10.43 (3.48)	25.86 (28.14)	4.78 (2.13)	6.11 (1.18)	10.90 (9.69)	9.26 (6.06)
Quality filtered, counts (SD)		46.00 (36.72)	33.33 (29.67)	14.67 (23.69)	125.67 (217.66)	10.67 (2.31)	16.33 (25.70)	557.62 (1200.76)	615.75 (1163.62)
Complexity filtered, counts (SD)		910.67 (775.48)	745.00 (659.60)	369.33 (567.40)	3168.67 (5438.11)	220.67 (163.57)	308.00 (526.55)	535.97 (884.46)	506.23 (455.16)
Size filtered, millions (SD)		0.63 (0.34)	2.26 (2.99)	0.68 (0.40)	2.12 (2.92)	0.90 (0.48)	0.49 (0.50)	1.94 (1.51)	2.39 (1.82)
Good quality reads*									
	Millions (SD)	8.07 (3.35)	14.44 (11.60)	9.75 (3.10)	23.74 (25.23)	3.88 (2.00)	5.62 (0.84)	8.96 (8.89)	6.88 (4.64)
	Percentage (SD)	92.62 (2.54)	90.35 (6.98)	93.93 (2.37)	94.15 (3.26)	79.60 (8.86)	92.62 (6.35)	77.76 (15.31)	74.95 (11.08)
miRNA									
	Millions (SD)	0.26 (0.19)	1.09 (1.57)	0.27 (0.19)	0.98 (1.14)	0.25 (0.07)	0.15 (0.13)	2.05 (2.50)	1.33 (1.42)
	Percentage (SD)	3.02 (1.73)	4.97 (4.92)	2.47 (1.52)	3.75 (0.54)	7.41 (3.44)	2.47 (1.97)	22.43 (16.01)	20.21 (13.22)
rRNA									
	Millions (SD)	2.34 (1.82)	3.12 (2.71)	1.57 (1.72)	5.74 (9.19)	0.72 (0.38)	0.90 (1.08)	0.92 (0.97)	0.81 (0.72)
	Percentage (SD)	24.72 (16.01)	20.36 (14.62)	14.84 (15.37)	13.41 (15.42)	19.55 (5.14)	15.13 (16.99)	11.11 (7.75)	11.49 (5.78)
tRNA									
	Millions (SD)	1.72 (0.58)	3.37 (1.51)	3.75 (1.80)	6.35 (3.00)	0.84 (0.64)	2.47 (1.47)	1.13 (1.17)	1.14 (0.94)
	Percentage (SD)	27.51 (23.37)	32.53 (27.16)	41.04 (20.74)	43.47 (23.59)	18.65 (9.43)	45.24 (26.80)	13.93 (6.85)	17.79 (7.70)
Unknown									
	Millions (SD)	3.75 (1.92)	6.86 (6.80)	4.16 (1.67)	10.66 (12.55)	2.07 (0.97)	2.11 (0.67)	4.87 (5.88)	3.59 (2.62)
	Percentage (SD)	44.76 (6.35)	42.14 (11.63)	41.65 (5.12)	39.37 (8.36)	54.40 (3.75)	37.15 (7.89)	52.53 (16.01)	50.51 (13.55)

^{*}Reads after filtering low quality, low complexity and short (<18nt) sequences

673

674

675

676

677

678

679

680

681

682

683

684

685

686

687

SM, Severe malaria; UM, Uncomplicated malaria; niE, non-infected erythrocytes; 3D7-iE, non-adherent 3D7-infected erythrocytes; ePCR-iE, adherent FCR3 expression endothelial receptor of protein C-infected erythrocytes; three replicates of the media collected from each cytoadhesion assay after one (t1) and 24 hours (t24)

Table 2: Characteristics of Mozambican children with severe and uncomplicated malaria recruited in 2006 (discovery) and 2014 (validation).

			2006			2014	
	•	UM	SM		UM	SM	
		N=39	N=44	p value	N=30	N=40	p value
Age# (year), mean (SD)		2.3 (1.1)	2.4 (1.3)	0.671	2.2 (1.3)	2.8 (1.2)	0.419
Sex, n (%)							
	Men	24 (62)	28 (64)	1.000	18 (60)	21 (52.5)	0.532
	Women	15 (38)	16 (36)		12 (40)	19 (47.5)	
HRP2 (ng/ml),GM (SD)		71.3 (10.7)	331.4 (40.7)	<0.001	24.1 (4.9)	78.7 (12.2)	0.038
aDCD (parasitas/ul) CM (S	יחי	2084.9	7976.1	0.004	72845.9	94099.6	0.549
qPCR (parasites/μl), GM (SD)		(302.5)	(1079.6)		(7193.9)	(8716.0)	
Splenomegaly, n (%)							
	No	33 (85)	21 (48)	0.001	ND	27 (67.5)	NA
	Yes	6 (15)	23 (52)		ND	13 (32.5)	
Hepatomegaly, n (%)							
	No	38 (97)	35 (80)	0.016	ND	35 (87.5)	NA
	Yes	1 (3)	9 (20)		ND	5 (12.5)	
Hyperlactatemia, n (%)							
	No	10 (26)	5 (11)	0.152	26 (86.7)	27 (67.5)	0.064
	Yes	29 (74)	39 (89)		4 (13.3)	13 (32.5)	
Temperature (°C), mean (SD)		38.0 (1.6)	38.5 (1.1)	0.093	38.0 (1.3)	38.2 (1.4)	0.437
Weight (Kg), mean (SD)		11.3 (2.8)	11.0 (2.8)	0.599	12.3 (2.9)	12.7 (3.3)	0.476
Platelets (10 ⁹ /L), mean (SD)		156.7 (86.8)	115.8 (66.8)	0.018	149.0 (89.7)	95.3 (69.3)	0.001
Glucose ^a (mM), mean (SD)		6.2 (1.5)	5.9 (1.8)	0.391	6.6 (1.3)	6.0 (2.6)	0.165
WBC (10°/L), mean (SD)		9.9 (4.1)	10.2 (3.9)	0.774	9.7 (3.8)	9.6 (5.0)	0.929
Neutrophils [¢] (%), mean (SD)		54.1 (16.7)	54.4 (14.3)	0.940	50.7 (20.6)	58.9 (13.7)	0.447
Lymphocytes (%), mean (SD)		39.4 (17.9)	36.3 (12.6)	0.374	26.1 (17.1)	25.6 (12.2)	0.995
Lactate (mM), mean (SD)		3.0 (1.7)	4.7 (3.6)	0.009	2.8 (2.2)	3.6 (2.4)	0.035
Severe malaria syndromes,	, n (%)						
	Prostration		33 (75.0)			30 (75.0)	
	Acute respiratory distress		18 (40.9)			19 (47.5)	
	Severe anaemia		17 (38.6)	7 (38.6) 7 (17.5)			
	Multiple seizures		11 (25.0)			24 (60.0)	
	Cerebral malaria		2 (4.5)			7 (17.5)	
	Hypoglycaemia		2 (4.5)			2 (5.0)	

Continuous data = Mann Whitney test; categorical data = Chi-square test

SM, Severe malaria; UM, Uncomplicated malaria; HRP2, Histidine-rich protein 2: WBC, White blood cells; GM, Geometric mean; SD, Standard deviation; ND, not determined; NA, not applicable

No data of 1 sample (UM=1) in 2014 study

No data of 3 sample (SM=2; UM=1) in 2014 study

688

689

697

698 699 700

No data of 4 samples (SM=4) in 2014 study
No data of 3 samples (SM=3) in 2014 study

Table 3: Association of miRNA levels with severe malaria, symptoms of severity and Plasmodium falciparum cytoadhesion. Positive FoldChange indicates overexpression in severe malaria and symptoms of severity compared to uncomplicated malaria as well as parasites showing cytoadhesion compared to none.

miRNA	baseMean	log2FoldChange	padj				
Clinical data							
Severe malaria (N=44 vs 39)							
hsa-miR-122-5p	19929.69	1.67	0.001				
Severe anaemia (N=17 vs 39)							
hsa-miR-4492	17.34	2.81	0.046				
hsa-miR-4497	293.66	2.18	0.046				
Prostration (N=33 vs 39)							
hsa-miR-122-5p	20677	1.89	0.001				
hsa-miR-6087	5.36	2.39	0.033				
hsa-miR-511-5p	126.67	1.36	0.040				
Acidosis or respiratory distre	ss (N=18 vs 39)						
hsa-miR-122-5p	13367.43	2.21	<0.001				
hsa-miR-4497	272.39	2.05	0.07				
Cytoadhesion data							
Platelet-mediated agglutination (N=50 vs 19)							
hsa-miR-3158-3p	1180.96	-2.26	<0.001				
hsa-miR-320a	22005.69	-1.48	0.001				
hsa-miR-4492	18.33	2.78	0.002				
hsa-miR-1290	1011.34	-1.38	0.014				
hsa-miR-320b	1191.44	-1.23	0.014				
hsa-miR-320c	408.32	-1.29	0.014				
hsa-miR-1246	3907.45	-1.32	0.019				
hsa-miR-6741-5p	48.11	-1.81	0.023				
hsa-miR-1228-5p	82.73	-1.88	0.023				
hsa-miR-3195	16.35	2.21	0.023				
hsa-miR-7706	334.86	-1.00	0.023				
gC1qR (N=35 vs 34)							
hsa-miR-1-3p	622.35	2.09	0.003				

Total number of miRNAs were 1450 in RNA sequencing data;

707

708

709

710

714

715

716

717

718

719

baseMean = Mean normalized expression of the miRNAs in all the samples;

padj = adjusted for multiple testing by the Benjamini-Hochberg method

Technical Appendix

Material and Methods

Study population

720

721

722

723

724

725

726

727

728

729

730

731

732

733

734

735

736

737

738

739

740

741

742

743

Clinical malaria was defined as the presence of fever (axillary temperature ≥ 37.5°C) with an asexual parasitemia of $Pf > 500/\mu L$. Children with severe malaria (SM) were those with at least one of the following symptoms: cerebral malaria (Blantyre Coma Score ≤2), severe anaemia (SA, packed cell volume <15% or haemoglobin <5g/dL), acidosis or acute respiratory distress (ARD, lactate >5mM and/or chest in-drawing or deep breathing), prostration (inability to sit or breastfeed in children old enough to do so based on their age), hypoglycaemia (blood glucose <2.2mM) and multiple seizures (≥2 convulsions in the preceding 24h) following the modified WHO criteria (1). Children with uncomplicated malaria (UM) were those with clinical malaria but not presenting any signs/symptoms of severity mentioned above (2). The presence of concomitant bacteraemia was tested in all SM cases using blood cultures and children with positive bacteraemia were excluded. Children with SM were treated according to Mozambican national guidelines with parenteral quinine in 2006 or parenteral artesunate (complemented with an oral artemisinin-based combination therapy) in 2014, and those with UM were treated with a combination of oral amodiaguine and sulfadoxine-pyrimethamine (Fansidar®) in 2006 or with artemether-lumefantrine (Coartem®) in 2014. Ten ml of heparinized blood was collected from study participants and processed within 2 hours after collection. Filter paper dried blood spots of 60µL blood were prepared from the vacutainer blood. After centrifugation at 1000rpms for 10minutes at 4°C, plasma was stored at -20°C. The 2014 study was conducted as a quasi-exact repetition of the 2006 study, the only

19th Dec Gupta et al

difference being that cases and controls were matched by parasitaemia level. Biochemistry parameters (glucose and lactate) and a full blood count were performed for each patient using Vitros DT60 and Sysmex Kx21 analyzers, respectively.

Parasitological determinations

Histidine-rich protein 2 (HRP2) levels were quantified using commercially available enzyme-linked immunosorbent assay kits (Malaria Ag CELISA; Cellabs Pty. Ltd., Brookvale, New South Wales, Australia) and an in-house highly sensitive quantitative bead suspension array based on Luminex technology. In brief, plasma samples were incubated overnight at 4°C with 2000 magnetic beads to a final dilution of 1:10. After washing, beads were sequentially incubated with 100 μL of in-house biotinylated antibody α-HRP2 (MBS832975, MyBiSource, San Diego, CL) at 1 μg/ml and with streptavidin-PE (42250-1ML, Sigma Aldrich, St. Louis, MO) at 1:1000 dilution. Finally, beads were washed and re-suspended in assay buffer, and the plate was read using the Luminex xMAP® 100/200 analyser (Luminex Corp., Austin, TX). A minimum of 50 microspheres per analyte were acquired and results were exported as crude median fluorescent intensity (MFI). Background (blank) MFIs were subtracted and normalized to account for plate to plate variation. Quantification was performed against a 5-parameter logistic regression curve fitted from a calibration curve consisting of recombinant protein HRP2 type A (890015, Microcoat GmbH, Germany).

Pf cytoadhesion assays

Human brain microvascular endothelial cells (Innoprot, Reference P10361) were cultured in 12 well-plates following the supplier's recommendations and were left until 40% confluency was achieved. HBE cells were incubated in triplicate with *Pf*-iEs at trophozoite stage of the ePCR-

binding FCR3 strain (ePCR-iE; which expresses the PfEPM1 protein that binds to ePCR receptor) and 3D7 strain (3D7-iE; a strain without the protein that binds to ePCR receptor) with 5% of both parasitemia and haematocrit. Non-infected erythrocytes were used as negative control. The cellconditioned media of each group were collected after 1hr (t1) and 24hrs of stimulation (t24). Next day, HBE cells were stimulated as described above, after 1-hour incubation in agitation, cells were washed at least 10 times with binding media and fixed with 2% glutaraldehyde (SIGMA) in PBS (Gibco) overnight to assess adhesion by light microscopy. After washing with water, cells were stained with 10% Giemsa. iE and niE bound were counted in six different wells per assay in at least 500 nuclei cell per well. Results were presented as the number of adhered iE per 500 nuclei of cells. Estimation of Pf adhesion to purified receptors (CD36, CD54 and g1CqR) as well as plateletmediated (PM)-agglutination and rosetting was performed as described elsewhere (2, 3). Cytoadherence was defined as positive only if the number of iEs bound per mm² was greater than the mean binding plus 2 standard deviations to Duffy-Fc coated petri dishes. Pf isolates were considered positive for PM clumping if the frequency of clumps was higher in the presence of platelets than in buffer-control and for rosetting if the frequency of rosettes was higher than 2% (2, 4).

Small RNA sequencing

769

770

771

772

773

774

775

776

777

778

779

780

781

782

783

784

785

786

787

788

789

790

791

792

793

Before RNA extraction, the level of haemolysis in plasma samples was assessed by spectrophotometry (EPOCH, BioTek) at a wavelength of 414nm (absorbance peak of free haemoglobin). Samples were classified as non-haemolysed if the optical density at 414nm was less than 0.2 (5). RNA was extracted from cell-conditioned media (3ml) and plasma samples (1ml) using the miRNeasy tissues/cells kit and miRNeasy Plasma/Serum kit (Qiagen), respectively, with the use of 5μg UltraPureTM glycogen/sample (Invitrogen). Given that the plasma samples were

795

796

797

798

799

800

801

802

803

804

805

806

807

808

809

810

811

812

813

814

815

816

817

818

19th Dec Gupta et al

conserved in heparin, RNA was precipitated with LiCl as described elsewhere (6). Purified RNA quality and quantity were determined using the Bioanalyzer (Agilent Technologies) followed by preparation of libraries using NEBNext® Small RNA Library Prep Set for Illumina® (New England Biolabs), then separation of libraries in polyacrylamide gels (Novex, Invitrogen). The Bioanalyzer was again used to quantify and assess the size of the libraries. Further, libraries were pooled at the same equimolar concentrations and no more than 18 libraries were sequenced in the same lane using a HiSeq 2000 (Illumina) platform following the protocol for small RNAs (7). A previously published pipeline was used to assess the sequencing quality, identification and quantification of small RNAs and normalization (7). First, a quality control (QC) was conducted using FASTX-Toolkit and FastQ Screen. After adaptor removing, reads with the following features were removed: 1) Reads <18nt, 2) Mean PHRED scores <30 and 3) Low complexity reads based on the mean score of the read. Good quality reads were then annotated to main RNA categories (tRNA, rRNA and miRNAs), and miRNA complexity was estimated as the number of distinct miRNAs that were observed in each sample. Finally, contamination with RNA from other species was evaluated by mapping reads to clade-specific mature miRNA sequences extracted from miRBase v21 (8). The tested species categories include animal sponges, nematodes, insects, lophotrochozoan, echinoderms, fish, birds, reptiles, rodents and primates. Sequences that passed the QC were subjected to the segBuster/segCluster tool that retrieves miRNA and isomiRs counts (9, 10). To detect miRNAs and isomiRs, reads were mapped to the precursors and annotated to miRNAs or isomiRs using miRBase version 21 with the miraligner (9). DESeq2 R package v.1.10.1 (R version 3.3.2) (11) was used to perform an internal normalization where the counts for a miRNA in each sample were divided by the median of the ratios of observed counts to the geometric mean of each corresponding miRNAs over all samples.

Reverse transcriptase quantitative PCR

Fifty μ l of plasma from the Mozambican children recruited in 2014 with no haemolysis were used for RNA extraction as described above. A synthetic RNA mimicking ath-miR-159a (*Arabidopsis thaliana*; Metabion) was added after lysis reaction at a final concentration of 1.5pM. cDNA synthesis and RT-qPCR [ABI PRISM 7500 HT Real-Time System (Applied Biosystems, Foster City, USA)] were performed using the TaqMan® Advanced miRNA assays. A standard curve of five serially diluted points was prepared with cDNA of six randomly selected samples and was run in triplicate for each miRNA. Results were normalized using a combination of endogenous controls (ECs). The selection of ECs was based on the following criteria: a) reported in scientific literature as previously used as ECs (12, 13), b) coefficient of variance (CV) of normalized counts across all samples \leq 5%, c) basemean \geq 3000, d) standard deviation \leq 1 and e) log₂fold change between SM and UM patients \leq 1. Finally, the best two ECs tested as housekeepings using the NormFinder (14) were used for normalization of RT-qPCR data. miRNA relative expression levels (RELs) were calculated with the 2^{-ACt} method, where Δ Ct = [Ct (miRNA) – Mean Ct (ECs)], considering efficiencies of 100% for all the miRNAs and ECs (12).

In silico analysis

- The selected miRNAs were screened through four different gene target prediction programs:
- DIANA-microT-CDS (15), MiRDIP (16), MirGate (17), and TargetScan
- (http://www.targetscan.org/vert 71/). Identified gene targets of each program were compared using

an online tool Venny2.1.0 (http://bioinfogp.cnb.csic.es/tools/venny/). The gene targets that occurred

in more than one database were selected and screened through the miRTarBase (18) online program

to check if these genes have been experimentally validated previously. These gene targets were anticipated to be true positive targets present at detectable levels in field samples. The identified gene targets were further analysed by DAVID 6.8 using *Homo sapiens* as the reference species. Genes were clustered to Gene Ontology terms and KEGG pathways (fold enrichment >1.5 and p <0.05).

Statistical analysis

Differential expression of miRNAs and isomiRs was assessed using DESEq2 and IsomiRs packages in R (9, 10), which use negative binomial generalized linear models adjusted for multiple testing with the false discovery rate (FDR) by the Benjamini-Hochberg method (19). Those with an FDR of 5% or below were selected for posterior analysis. Analysis of the modification in the bases of the seed region was carried using isomiR package to determine a possible change in the target messenger RNAs. Mann-Whitney U and χ^2 (Chi-square) tests were performed to compare continuous data and categorical data, respectively. Spearman correlation analysis was performed to assess the correlation of miRNA RELs (log transformed) with log transformed HRP2 levels. A two-sided p<0.05 was considered statistically significant. All statistical analyses were performed using R 3.3.2 in Linux-based system and graphs were prepared with GraphPad.

868

869

870

871

872


873

874

875

876

Figure 1: Cytoadhesion assay: Infected erythrocytes (iEs) with human brain endothelial (HBE) cells stained with Giemsa and visualised at 200X. A) non-infected erythrocytes (niE), B) nonadherent 3D7-infected erythrocytes (3D7-iE), C) adherent FCR3 expression endothelial receptor of protein C-infected erythrocytes (ePCR-iE) and D) three group's comparison for infected erythrocytes adhered to HBE cells. Bars represent the mean and T line the standard deviation. p values were calculated using an unpaired t-test.



877

878

879

880

881


882

883

884

885

Figure 2: RT-qPCR Ct values of exogenous (ath-miR-159a) and endogenous (hsa-miR-191-5p, hsa-miR-30d-5p and hsa-miR-148a-3p) controls in severe malaria (SM) and uncomplicated malaria (UM) groups. Distributions were compared using Mann-Whitney U test. T bars represent median and Interquartile Ranges (IQR).



Gupta et al

Table 1: Number of reads, quality control and number of different miRNAs detected in cellconditioned media of human brain endothelial cells exposed to cytoadherent (ePCR-iE), noncytoadherent (3D7-iE) P. falciparum infected and non-infected erythrocytes (niE).

19th Dec

886

887

888

889

891

892

893

Sample	Total reads	Quality	Complexity	Length	Good quality	rRNA	tRNA	miRNA	Unknown	Differen
		filtered	filtered	filtered	reads					miRNAs
t1_niE-1	4681945	4	34	337979	4343966	270763	2366921	75187	1631095	231
t1_niE-2	11411515	62	1191	562570	10848945	3679590	1543964	252710	5372681	212
t1_niE-3	10012344	72	1507	1000811	9011533	3064588	1243462	449402	4254081	465
t1_3D7-iE-1	12991483	2	81	850480	12141003	912334	5575569	369947	5283153	233
t1_3D7-iE-2	6470351	0	4	225621	6244730	281177	3677882	46237	2239434	240
t1_3D7-iE-3	11824305	42	1023	965079	10859226	3529982	1986414	392862	4949968	256
t1_ePCR-iE-1	5571743	8	60	1450083	4121660	585628	982702	215775	2337555	363
t1_ePCR-iE-2	2366064	12	215	591454	1774610	434035	137804	201756	1001015	122
t1_ePCR-iE-3	6400097	12	387	651993	5748104	1148564	1398684	322921	2877935	181
t24_niE-1	33411780	61	1326	5688689	27723091	5762892	4456704	2896826	14606669	157
t24_niE-2	10227177	37	881	899113	9328064	3242238	1646379	328760	4110687	137
t24_niE-3	6482702	2	28	203593	6279109	347523	4011059	58043	1862484	119
t24_3D7-iE-1	14668936	0	51	730638	13938298	663276	7270210	498805	5506007	101
t24_3D7-iE-2	5034919	0	7	156980	4877939	208106	2998788	161344	1509701	146
t24_3D7-iE-3	57868438	377	9448	5474274	52394164	16356374	8786690	2280235	24970865	230
t24_ePCR-iE-1	6163503	2	2	156258	6007245	212547	3808455	92989	1893254	120
t24_ePCR-iE-2	7262082	46	916	1057919	6204163	2149075	896948	293743	2864397	223
t24_ePCR-iE-3	4907246	1	6	246902	4660344	336305	2697248	52875	1573916	118

Table 2: miRNAs differentially expressed in cell-conditioned media of human brain endothelial cells when exposed to niE and compared with ePCR-iE after one hour incubation. Positive FoldChange indicates overexpression in niE.

hasaMaan	log?FoldChange	padj
3628.925319	7.106957417	2.20E-64
8513.8312	6.854156394	2.86E-33
663.0033186	5.589928255	2.74E-29
958.7797602	6.480019242	3.64E-22
359.7886812	6.949480635	3.31E-19
186.7263031	9.764657543	1.81E-13
3014.137094	4.242367581	1.25E-12
70.86488948	9.209904393	3.00E-12
72.96215294	8.781293485	4.09E-12
572.9246948	3.850563079	7.29E-12
60.38153154	7.465472022	4.02E-11
3583.963415	10.60183039	6.42E-11
1848.704656	3.167278515	3.68E-10
121.4605639	5.034134649	3.78E-10
159.1304428	4.762393491	2.69E-09
28.41313356	7.592582565	5.34E-09
39.85412873	-4.344998011	9.19E-09
264.2422459	3.036225197	3.23E-08
1648.646951	2.426234941	5.38E-08
24.09578022	7.678294911	6.73E-08
6094.803676	2.906210556	8.46E-08
518.887784	2.698437793	9.62E-08
45.25401955	5.187956688	1.71E-07
412.4688189	-2.480558611	2.01E-07
102.3727512	4.139411714	2.36E-07
1018.820725	2.668213456	5.27E-07
29.59956282	5.9824388	5.65E-07
27.95214056	5.751583995	6.65E-07
	663.0033186 958.7797602 359.7886812 186.7263031 3014.137094 70.86488948 72.96215294 572.9246948 60.38153154 3583.963415 1848.704656 121.4605639 159.1304428 28.41313356 39.85412873 264.2422459 1648.646951 24.09578022 6094.803676 518.887784 45.25401955 412.4688189 102.3727512 1018.820725 29.59956282	3628.925319 7.106957417 8513.8312 6.854156394 663.0033186 5.589928255 958.7797602 6.480019242 359.7886812 6.949480635 186.7263031 9.764657543 3014.137094 4.242367581 70.86488948 9.209904393 72.96215294 8.781293485 572.9246948 3.850563079 60.38153154 7.465472022 3583.963415 10.60183039 1848.704656 3.167278515 121.4605639 5.034134649 159.1304428 4.762393491 28.41313356 7.592582565 39.85412873 -4.344998011 264.2422459 3.036225197 1648.646951 2.426234941 24.09578022 7.678294911 6094.803676 2.906210556 518.887784 2.698437793 45.25401955 5.187956688 412.4688189 -2.480558611 102.3727512 4.139411714 1018.820725 2.668213456 29.59956282 5.9824388

895

896

897

898

hsa-miR-146a-5p	395.7308176	2.295825898	1.07E-06
hsa-miR-486-3p	442.3385331	-2.280314186	1.42E-06
hsa-miR-199b-5p	17.69789788	6.652284259	1.65E-06
hsa-miR-148a-3p	21311.06097	2.967223068	2.14E-06
hsa-miR-769-5p	78.16221633	3.454304058	2.22E-06
hsa-miR-132-3p	13.41828033	6.795969882	2.82E-06
hsa-miR-504-5p	16.20689324	6.842868855	3.34E-06
hsa-miR-92a-3p	65823.55513	-2.10142854	4.67E-06
hsa-miR-330-3p	53.90163431	3.129351136	4.88E-06
hsa-miR-200c-3p	15.27230031	6.716323846	5.34E-06
hsa-miR-486-5p	186570.8541	-2.309900141	5.98E-06
hsa-miR-338-5p	16.14897785	6.511596255	7.43E-06
hsa-miR-183-5p	757.7566497	-2.260214693	7.87E-06
hsa-miR-1273h-5p	11.10031853	6.530890359	1.55E-05
hsa-miR-342-5p	93.52411001	3.308610483	4.55E-05
hsa-miR-326	16.42493563	5.988631002	4.61E-05
hsa-miR-618	15.6716072	6.016209684	4.61E-05
hsa-miR-191-5p	2983.128623	1.523838499	7.79E-05
hsa-miR-27a-3p	285.7014296	1.731405393	7.96E-05
hsa-miR-328-3p	271.7224572	2.170776673	7.96E-05
hsa-miR-451a	14357.385	-1.83622576	9.53E-05
hsa-miR-3614-5p	9.33818402	6.123669779	0.000106957
hsa-miR-30e-3p	815.6225605	2.360699038	0.000125365
hsa-miR-3653-3p	9.955406247	6.067314627	0.000138372
hsa-miR-16-2-3p	99.02227371	-2.704373872	0.000138392
hsa-miR-941	1372.569505	2.112993367	0.000155687
hsa-miR-1273h-3p	8.79013326	5.927996135	0.000189765
hsa-miR-584-5p	74.74437394	-2.177917358	0.000200673
hsa-miR-361-5p	31.19551383	3.652271942	0.000286557
hsa-miR-423-5p	9496.481452	-1.666500408	0.000301254
hsa-miR-425-3p	23.4899942	3.50770916	0.000497233
hsa-miR-1908-5p	5.40110314	-6.802848578	0.000500329
hsa-miR-144-5p	73.08790204	-2.608545423	0.000614181
hsa-miR-148a-5p	7.077958372	5.991607608	0.000826919
hsa-miR-3960	21.82641113	-3.014306593	0.000826919
hsa-miR-92b-3p	284.8388438	-1.662148164	0.001252142

hsa-miR-625-3p	147.3917485	2.170185206	0.001322084
hsa-miR-320a	3462.527306	-1.402939938	0.00139293
hsa-miR-345-5p	22.71828536	3.943197206	0.00139293
hsa-miR-1260a	50.29735001	2.615764632	0.001605391
hsa-let-7i-5p	12361.71358	-1.302787012	0.001797592
hsa-miR-619-5p	22.7811983	3.161529188	0.001900387
hsa-miR-122-5p	3385.264898	-1.584467253	0.002340813
hsa-miR-340-5p	46.36446243	2.653771404	0.002544196
hsa-miR-144-3p	48.36612972	-2.49500384	0.002555714
hsa-miR-126-3p	892.3500608	-1.625098791	0.003126621
hsa-miR-543	129.0107724	-1.784228026	0.003228785
hsa-miR-22-3p	198.2421283	-1.339256703	0.003317174
hsa-miR-125a-3p	25.61739412	2.647707932	0.0045958
hsa-miR-26b-3p	5.972701619	5.518835758	0.0045958
hsa-miR-365a-3p	53.55418216	2.123552072	0.0045958
hsa-miR-365b-3p	53.55418216	2.123552072	0.0045958
hsa-let-7b-5p	11122.0756	-1.385051301	0.004654547
hsa-miR-340-3p	9.403598252	4.19564441	0.007285806
hsa-miR-3158-3p	143.2936325	-1.487178473	0.00782372
hsa-miR-3909	4.660678895	5.033669701	0.008065745
hsa-miR-505-3p	19.61789922	3.184975964	0.009512761
hsa-miR-96-5p	6.228218724	-4.412956083	0.01160297
hsa-miR-92b-5p	15.60484631	-2.774216268	0.011905118
hsa-miR-5684	14.25740308	-3.392469579	0.012209695
hsa-miR-574-3p	151.5421548	1.44861864	0.012209695
hsa-miR-589-5p	112.3400591	1.712421621	0.012209695
hsa-miR-1260b	38.28153971	1.901084012	0.015737938
hsa-miR-17-5p	56.12478112	-1.912960954	0.017636633
hsa-miR-4488	301.3772581	1.686545438	0.019800269
hsa-miR-3150b-3p	9.284489454	3.713227496	0.020280067
hsa-miR-503-5p	39.07218516	-1.757011842	0.023641179
hsa-miR-24-2-5p	7.48136792	3.967586096	0.024393346
hsa-miR-4508	74.78488456	-1.444481229	0.024393346
hsa-miR-193a-5p	184.9649622	1.410027061	0.025848637
hsa-miR-148b-3p	604.5039106	1.071494091	0.025962098
hsa-miR-24-3p	347.9262528	1.011562924	0.025962098

hsa-miR-26a-5p	2978.105792	1.023914595	0.030449772
hsa-let-7a-5p	14867.14987	-1.186931323	0.032443997
hsa-miR-1180-3p	56.26387509	-1.461006415	0.032443997
hsa-miR-128-3p	443.1001246	1.234565868	0.032663654
hsa-miR-4732-5p	37.4933489	-1.669985619	0.033292936
hsa-miR-194-5p	19.87025713	-2.652995088	0.035040129
hsa-let-7e-5p	315.5665007	-1.266168593	0.036277702
hsa-miR-222-3p	1950.75622	-1.054430196	0.04170154
hsa-miR-744-5p	307.4576353	1.101237911	0.04395607
hsa-miR-93-3p	19.14613315	2.21447109	0.04444623
hsa-miR-28-5p	15.19613321	2.619036378	0.047605172

Total number of miRNAs were 363 in RNA sequencing data;

19th Dec

 $base Mean = Mean \ normalized \ expression \ of \ the \ miRNAs \ in \ all \ the \ samples;$

 $padj = adjusted \ for \ multiple \ testing \ by \ the \ Benjamini-Hochberg \ method;$

niE, non-infected erythrocytes; ePCR-iE, adherent FCR3 expression endothelial receptor of protein C-infected erythrocytes

19th Dec Gupta et al

Table 3: miRNAs differentially expressed in cell-conditioned media of human brain endothelial cells when exposed to 3D7-iE and compared with ePCR-iE after one hour incubation. Positive FoldChange indicates overexpression in 3D7-iE.

miRNA	baseMean	log2FoldChange	padj
hsa-miR-150-5p	3628.925319	6.447621237	8.41E-53
hsa-miR-1246	8513.8312	6.448500505	2.44E-29
hsa-miR-342-3p	663.0033186	4.805719054	1.87E-21
hsa-miR-1290	958.7797602	6.047501723	3.28E-19
hsa-miR-143-3p	3014.137094	4.973540967	3.06E-17
hsa-miR-223-5p	359.7886812	6.431781207	1.96E-16
hsa-miR-4791	186.7263031	10.38932761	2.56E-15
hsa-miR-145-5p	72.96215294	8.773111499	5.33E-12
hsa-miR-23a-3p	1648.646951	2.919080408	3.83E-11
hsa-miR-146b-5p	572.9246948	3.720217317	5.04E-11
hsa-miR-423-5p	9496.481452	-2.845800299	1.45E-10
hsa-miR-223-3p	3583.963415	10.40824443	1.77E-10
hsa-miR-28-3p	1018.820725	3.236927509	7.54E-10
hsa-miR-197-3p	1848.704656	3.045327492	2.21E-09
hsa-miR-3690	70.86488948	7.939040485	3.04E-09
hsa-miR-363-3p	412.4688189	-2.752949366	7.66E-09
hsa-miR-451a	14357.385	-2.623190083	1.10E-08
hsa-miR-4732-3p	39.85412873	-4.446862598	1.22E-08
hsa-miR-4286	28.41313356	7.221117949	3.72E-08
hsa-miR-1299	102.3727512	4.296659106	8.94E-08
hsa-miR-146a-5p	395.7308176	2.416585365	3.27E-07
hsa-miR-320a	3462.527306	-2.147110555	4.06E-07
hsa-miR-150-3p	60.38153154	5.841471731	5.53E-07
hsa-miR-3158-3p	143.2936325	-2.671376413	6.03E-07
hsa-miR-199b-5p	17.69789788	6.756414418	1.41E-06
hsa-miR-326	16.42493563	7.000378659	1.46E-06
hsa-miR-92a-3p	65823.55513	-2.206241834	1.80E-06
hsa-miR-618	15.6716072	6.882512894	2.54E-06
hsa-miR-27a-5p	159.1304428	3.853017578	2.61E-06
hsa-miR-361-5p	31.19551383	4.557109213	3.99E-06

915

916

hsa-miR-766-3p	29.59956282	5.475435141	7.17E-06
hsa-miR-338-5p	16.14897785	6.585842515	7.56E-06
hsa-miR-1180-3p	56.26387509	-2.865258808	1.15E-05
hsa-miR-486-5p	186570.8541	-2.257048303	1.36E-05
hsa-miR-486-3p	442.3385331	-2.077360932	1.53E-05
hsa-miR-140-3p	6094.803676	2.378049094	1.89E-05
hsa-miR-1291	24.09578022	6.218174392	2.27E-05
hsa-miR-29a-3p	264.2422459	2.377846317	2.52E-05
hsa-miR-4508	74.78488456	-2.537316275	3.24E-05
hsa-miR-6842-3p	121.4605639	3.458457239	3.89E-05
hsa-miR-200c-3p	15.27230031	6.110652566	5.42E-05
hsa-miR-504-5p	16.20689324	6.10449083	5.42E-05
hsa-miR-582-3p	45.25401955	4.02067135	9.79E-05
hsa-miR-769-5p	78.16221633	2.900427661	0.000122239
hsa-miR-27a-3p	285.7014296	1.699710038	0.000132728
hsa-miR-625-3p	147.3917485	2.549490741	0.000132728
hsa-miR-340-5p	46.36446243	3.201883577	0.000214609
hsa-miR-144-3p	48.36612972	-3.0660485	0.000220627
hsa-miR-425-3p	23.4899942	3.724522238	0.000223367
hsa-miR-320b	420.1406035	-1.862313231	0.000276457
hsa-miR-365a-3p	53.55418216	2.655154806	0.000276457
hsa-miR-365b-3p	53.55418216	2.655154806	0.000276457
hsa-miR-132-3p	13.41828033	5.410556286	0.000380553
hsa-let-7i-5p	12361.71358	-1.47141141	0.000382512
hsa-miR-30e-3p	815.6225605	2.226049992	0.000382512
hsa-miR-92b-5p	15.60484631	-4.163857943	0.0003924
hsa-miR-146b-3p	27.95214056	4.242630881	0.000482005
hsa-miR-92b-3p	284.8388438	-1.785328471	0.000505668
hsa-miR-4732-5p	37.4933489	-2.594968757	0.000643162
hsa-miR-122-5p	3385.264898	-1.753744088	0.000704175
hsa-miR-144-5p	73.08790204	-2.558810315	0.00089817
hsa-miR-3653-3p	9.955406247	5.420823215	0.000963768
hsa-miR-330-3p	53.90163431	2.33736255	0.001216256
hsa-miR-2115-3p	6.041154984	5.834660721	0.001395787
hsa-miR-183-5p	757.7566497	-1.689145385	0.001439809
hsa-miR-1273h-3p	8.79013326	5.232979185	0.001476418

hsa-miR-1273h-5p	11.10031853	5.004655278	0.001837808
hsa-miR-345-5p	22.71828536	3.888926893	0.001844401
hsa-miR-361-3p	518.887784	1.669833063	0.001878529
hsa-miR-328-3p	271.7224572	1.756856697	0.002066471
hsa-miR-3614-5p	9.33818402	5.084630328	0.002066471
hsa-miR-1260a	50.29735001	2.56883531	0.002146885
hsa-miR-191-5p	2983.128623	1.22004135	0.002216696
hsa-miR-505-3p	19.61789922	3.426913927	0.00528521
hsa-miR-4685-3p	26.37952361	-2.212963535	0.006078573
hsa-miR-148a-3p	21311.06097	1.831991607	0.006860876
hsa-miR-126-3p	892.3500608	-1.523444179	0.007103832
hsa-let-7b-5p	11122.0756	-1.342668008	0.007601427
hsa-miR-5189-5p	4.690302347	-6.195706422	0.008125759
hsa-miR-4448	19.99074734	2.751420355	0.008596921
hsa-miR-28-5p	15.19613321	3.329553964	0.008697526
hsa-miR-619-5p	22.7811983	2.721712643	0.011008689
hsa-miR-5684	14.25740308	-3.504790338	0.011818106
hsa-miR-221-5p	30.33237403	2.235527273	0.014993794
hsa-miR-24-3p	347.9262528	1.101827408	0.015833224
hsa-miR-193a-5p	184.9649622	1.491052572	0.020130112
hsa-miR-22-3p	198.2421283	-1.113442482	0.021327869
hsa-miR-93-3p	19.14613315	2.52716344	0.021327869
hsa-miR-2110	117.7715931	-1.410612056	0.02301949
hsa-miR-342-5p	93.52411001	2.045398548	0.02301949
hsa-miR-543	129.0107724	-1.437070341	0.02604373
hsa-miR-155-5p	135.1369051	1.308204109	0.02781228
hsa-miR-152-3p	52.85362465	1.703147513	0.027818637
hsa-miR-584-5p	74.74437394	-1.39071939	0.029085671
hsa-let-7e-5p	315.5665007	-1.333615616	0.030343738
hsa-miR-1908-5p	5.40110314	-4.518938959	0.033717462
hsa-miR-16-2-3p	99.02227371	-1.642902948	0.035497673
hsa-miR-3150b-3p	9.284489454	3.477104992	0.037288673
hsa-miR-106a-5p	5.273323169	-4.723234986	0.046728731
hsa-miR-15b-5p	59.88239009	1.339085366	0.048947187

918

919

920

921

Total number of miRNAs were 363 in RNA sequencing data;

 $base Mean = Mean \ normalized \ expression \ of \ the \ miRNAs \ in \ all \ the \ samples;$

 $padj = adjusted \ for \ multiple \ testing \ by \ the \ Benjamini-Hochberg \ method;$

 $³D7\text{-}iE, non-adherent\ 3D7\text{-}infected\ erythrocytes;\ ePCR\text{-}iE,\ adherent\ FCR3\ expression\ endothelial\ receptor\ of\ protein\ C\text{-}infected\ erythrocytes}$

19th Dec Gupta et al

Table 4: Number of reads, quality control and number of different miRNAs detected in plasma from Mozambican children recruited in 2006.

922

Sample	Total reads	Quality	Complexity	Length	Good quality	rRNA	tRNA	miRNA	Unknown	Different
		filtered	filtered	filtered	reads					miRNAs
525881.3	10711219	1019	496	3093606	7617613	1831500	651064	807691	4327358	395
525884.4	13220660	803	702	3888349	9332311	966969	596303	1966978	5802061	574
525885.1	10702582	333	566	2319260	8383322	1232736	1136730	1751858	4261998	548
525887.5	13661026	1124	53	2762425	10898601	594196	670121	2832128	6802156	539
525889.9	26426632	1073	384	2617714	23808918	2136483	2578042	5776301	13318092	642
525891.2	9524995	439	270	1873951	7651044	699777	854636	1589401	4507230	593
525893.6	2162887	79	49	120186	2042701	127077	390794	440733	1084097	331
525896.7	17421782	1908	548	5626333	11795449	1265772	839750	1030609	8659318	341
525898.1	3320188	126	118	832015	2488173	142443	215289	1663216	467225	425
525899.8	5937637	296	454	1500015	4437622	572501	700764	517740	2646617	355
525903.0	14957552	2	276	2265449	12692103	1692270	3040674	1194073	6765086	292
525909.2	10293853	2128	224	3483287	6810566	768196	599146	1269410	4173814	412
544393.2	9208074	489	675	2151722	7056352	1496125	1507206	883567	3169454	501
544394.9	13598660	996	1250	6286338	7312322	1247933	758898	1477246	3828245	580
544395.6	16309029	973	1449	3847507	12461522	3653367	2378483	1189219	5240453	554
544396.3	7566573	276	197	1246660	6319913	627080	1632315	1027308	3033210	531
544397.0	6772398	266	222	1805393	4967005	1187429	550612	675373	2553591	498
544404.3	7386300	287	354	1583391	5802909	433117	555473	996837	3817482	581
544406.7	575642	0	1	94684	480958	34498	156803	223001	66656	337
544407.4	322699	7	47	33711	288988	26869	86815	40357	134947	199
544408.1	10702037	390	839	2161657	8540380	710955	2179306	1632353	4017766	663
544413.5	15424105	20	208	3016358	12407747	2130079	1918422	2473544	5885702	276
544415.9	15845270	581	585	4355557	11489713	1693453	1942665	3572255	4281340	757
544417.3	320995	6	47	49727	271268	79124	58275	53365	80504	229
544423.4	12314227	511	879	2620234	9693993	1146777	1257197	2022726	5267293	620
544425.8	6960365	244	319	1393757	5566608	452538	1278619	967048	2868403	473
544430.2	29411214	2681	2251	7142325	22268889	2330062	2430827	2447114	15060886	472
544431.9	12913067	374	771	2019212	10893855	1553982	2423487	2087189	4829197	298
544434.0	9194679	428	55	1158428	8036251	1187467	1514795	1642793	3691196	433
544436.4	10628594	352	242	1424162	9204432	1030961	2030035	2940439	3202997	465
544439.5	18820329	990	1239	3728346	15091983	1867354	2041446	1558034	9625149	659

19th Dec Gupta et al

566322.2	9096499	219	526	970253	8126246	222824	1176992	1440172	5286258	463
566323.9	12512273	307	147	681565	11830708	373103	468855	8338268	2650482	770
566324.6	7407842	271	230	799057	6608785	473056	1541802	2306487	2287440	644
566327.7	265530	5	26	39505	226025	23941	18230	86877	96977	274
566329.1	575470	7	48	23763	551707	59080	163228	133556	195843	311
566332.1	9282984	18	577	2188722	7094262	936251	1105618	2509571	2542822	310
566333.8	12485750	1976	85	3068214	9417536	1147898	945883	1973103	5350652	669
566335.2	16300010	1628	450	3430462	12869548	1439268	1267034	2367655	7795591	395
566353.6	12299560	520	92	4379950	7919610	1052903	619183	2088724	4158800	612
566355.0	2968770	0	79	1009357	1959413	328104	255943	440443	934923	160
566356.7	15403237	1053	1726	3642172	11761065	2419028	1509598	1633826	6198613	628
566358.1	8943757	529	1773	3677028	5266729	1105767	487154	1637474	2036334	454
566359.8	744578	20	72	58563	686015	35746	148801	79994	421474	288
566361.1	25792113	905	1378	7723560	18068553	1793988	2690970	6727806	6855789	580
566362.8	12021808	747	24	3274341	8747467	1603501	18940	10773	7114253	151
566364.2	1631464	99	104	556133	1075331	112855	251575	48887	662014	274
566365.9	19129131	2	966	1691465	17437666	2087295	2389159	7624018	5337194	399
566366.6	19623668	7037	92	5322923	14300745	1231391	1029852	1170845	10868657	467
566367.3	384010	3	32	97518	286492	22854	26912	122521	114205	150
579033.4	12761288	299	223	2438291	10322997	4471210	1076958	2371736	2403093	570
579034.1	7225891	25	2766	472409	6753482	472354	2250034	994990	3036104	465
579035.8	9863866	517	265	2370430	7493436	441043	567999	1734312	4750082	481
579036.5	145356	0	13	17436	127920	4210	11235	65688	46787	196
579037.2	1493408	4	82	338939	1154469	47182	229698	521844	355745	394
579038.9	10367363	371	1380	3078000	7289363	639425	1550985	991123	4107830	388
579040.2	9253151	13	408	2472738	6780413	384449	1761922	500022	4134020	373
579042.6	15960129	470	202	2728371	13231758	638919	3805700	1934893	6852246	380
579043.3	7089342	206	697	1602007	5487335	964876	1536510	687802	2298147	260
579045.7	1982823	2	433	143776	1839047	233623	490286	324346	790792	305
579046.4	1873456	486	38	806002	1067454	75715	60748	43809	887182	185
579048.8	1082686	1	50	185056	897630	54474	153016	135343	554797	200
579050.1	170063	2	27	17739	152324	17255	29933	23521	81615	160
579051.8	10722970	448	158	1708024	9014946	642574	2552986	1186376	4633010	313
579052.5	4228866	219	748	2256487	1972379	246201	433194	222570	1070414	146
579053.2	8618384	462	1092	1949499	6668885	354969	1025766	994142	4294008	319
579054.9	9386303	689	143	4284092	5102211	340702	1452895	638954	2669660	242

579055.6	3526717	94	80	1769909	1756808	199283	294707	223967	1038851	123
579058.7	1792508	133	10	997704	794804	53040	154970	126036	460758	242
579059.4	17665599	8	910	1746197	15919402	1020271	3146816	6390514	5361801	365
579060.0	11438101	537	771	3749312	7688789	618651	1015852	548212	5506074	300
								1109671		
579061.7	33311564	3	1496	2576915	30734649	2601559	5795176	6	11241198	442
579062.4	3451830	156	2	1762819	1689011	202947	239684	218299	1028081	116
579064.8	8994815	278	178	2721236	6273579	840779	987181	593171	3852448	161
579065.5	18176617	7425	386	6172449	12004168	781469	399288	948897	9874514	334
579068.6	5128830	305	256	1520699	3608131	300353	890927	810364	1606487	396
579069.3	45577321	37	4302	2027990	43549331	926339	3622063	5903995	33096934	786
579075.4	9827499	20	816	1032689	8794810	363164	665426	1692835	6073385	515
579077.8	10214090	344	167	1093407	9120683	1504424	989870	3501517	3124872	595
579078.5	4481826	234	167	2157860	2323966	119110	242195	281184	1681477	175
579079.2	1225321	30	72	869796	355525	78232	60481	95781	121031	204
598991.0	8703408	2	406	1378261	7325147	439304	989308	2636136	3260399	546
598993.4	7424401	473	236	3018779	4405622	292897	603224	430567	3078934	181

Table 5: Spearman correlations between ELISA based HRP2 levels and miRNA relative expression levels (RELs) in plasma samples from Mozambican children. HRP2 levels and miRNA RELs were log transformed.

miRNA	rho	p value				
Children recruited in 2006						
hsa-miR-10b-5p	0.415	0.020				
hsa-miR-378a-3p	0.422	0.020				
hsa-miR-4497	0.533	< 0.001				
Children recruited in 2014						
hsa-miR-122-5p	-0.016	0.892				
hsa-miR-320a	0.121	0.320				
hsa-miR-1246	0.066	0.588				
hsa-miR-1290	0.123	0.310				
hsa-miR-3158-3p	0.511	< 0.001				
hsa-miR-4497	0.401	< 0.001				

19th Dec

Table 6: PCR efficiencies of each miRNA used for RT-qPCR analysis.

miRNA	PCR efficiencies
hsa-miR-122-5p	99.6%
hsa-miR-320a	95.3%
hsa-miR-1246	98.4%
hsa-miR-1290	103.0%
hsa-miR-3158-3p	91.2%
hsa-miR-4497	96.9%
has-miR-191-5p	93.1%
hsa-miR-30d-5p	103.8%
hsa-miR-148a-3p	100.1%
ath-miR-159a	103.2%

19th Dec

Table 7: The predicted targets of the two miRNAs (hsa-miR-3158-3p and hsa-miR-4497) validated in children recruited in 2014.

hsa-miR-3158-3p	hsa-miR-4497
TXNIP	RUNX1
MAP3K9	CCNF
ZNF704	CTTN
BCL7A	FANCA
GATAD2B	NAB2
FBXO46	NF2
CHST15	NPY4R
FTSJ3	PRPS1
CTC1	TPM3
CABP7	UGT8
C20orf194	VEGFA
IGSF8	RAB9A
KLHL15	IRX5
NLK	BPNT1
NFASC	APPBP2
LMNB2	CD226
MRPS18A	ATP1B4
LSM4	SH2B1
XRCC6	SDF4
ZBTB39	MTPAP
UBXN2B	TMEM33
RRP7A	DUSP22
ZCCHC14	RAB22A
RANGAP1	TBC1D24

19th Dec

956

957

958

19th Dec Gupta et al

RAB3IP ZNF490

DSN1 AMOTL2

ANXA11 FBXL18

C22orf39 LRRC27

DDX6 ATP13A4

CDK2 HIST1H2AH

SP140L **ENAH**

ENPP5 CAMK2N2

GDAP1L1 C10orf71

FAM83C FOSL1

MMP15 MIPOL1

PLAG1 CCNY

NANOS1 PRPS1L1

MRTO4 **CBARP**

PIGQ LHFPL3

NLGN1 C8orf82

RTN2 PPAN-P2RY11

SAMD4A CASTOR2

PTPRJ

THSD7A

ZNF281

Table 8: Clustering results of DAVID analysis.

27th June

960

961

Category	Term	Genes	Fold	p	Benjamini p
			Enrichment	value	value
GOTERM_CC_DIR	GO:0030687~preribosome,	PPAN-P2RY11, FTSJ3,	25.136	0.006	0.647
ECT	large subunit precursor	MRTO4			
GOTERM_BP_DIR	GO:0007399~nervous system	IGSF8, NAB2, VEGFA,	4.875	0.007	0.977
ECT	development	NLGN1, BPNT1,			
		PRPS1			
GOTERM_CC_DIR	GO:0045335~phagocytic	RAB9A, ANXA11,	18.691	0.011	0.605
ECT	vesicle	RAB22A			
GOTERM_MF_DIR	GO:0000287~magnesium ion	NLK, MTPAP,	5.237	0.015	0.902
ECT	binding	PRPS1L1, BPNT1,			
		PRPS1			
GOTERM_BP_DIR	GO:0006015~5-phosphoribose	PRPS1L1, PRPS1	116.611	0.017	0.987
ECT	1-diphosphate biosynthetic				
	process				
GOTERM_BP_DIR	GO:0002175~protein	NFASC, UGT8	116.611	0.017	0.987
ECT	localization to paranode region				
	of axon				
GOTERM_BP_DIR	GO:0009156~ribonucleoside	PRPS1L1, PRPS1	93.288	0.021	0.974
ECT	monophosphate biosynthetic				
	process				
GOTERM_MF_DIR	GO:0004749~ribose phosphate	PRPS1L1, PRPS1	85.473	0.023	0.702
ECT	diphosphokinase activity				
GOTERM_CC_DIR	GO:0043231~intracellular	CTTN, MTPAP,	3.048	0.026	0.667
ECT	membrane-bounded organelle	RANGAP1, UGT8,			
		RUNX1, ATP13A4,			
		DDX6			
GOTERM_MF_DIR	GO:0019003~GDP binding	RAB9A, RAB22A,	11.871	0.026	0.641
ECT		PRPS1			
GOTERM_CC_DIR	GO:0005635~nuclear envelope	TMEM33, ANXA11,	6.112	0.027	0.602
ECT		ATP1B4, RANGAP1			
GOTERM_CC_DIR	GO:0030027~lamellipodium	ENAH, CTTN, NF2,	6.074	0.027	0.542
ECT		RAB3IP			
GOTERM_BP_DIR	GO:0030913~paranodal	NFASC, UGT8	66.634	0.029	0.978
ECT	junction assembly				
	J				

27 th June	it is made available	under a CC-BY-NC-ND 4	.u international lice	ense .		Gupta et al
ECT	mRNA processing body	DDX6				
GOTERM_MF_DIR	GO:0030371~translation	NANOS1, SAMD4A	38.851	0.049	0.798	
ECT	repressor activity					
GOTERM_CC_DIR	GO:0001726~ruffle	CTTN, NF2, RAB22A	8.099	0.052	0.674	
ECT						
GOTERM_BP_DIR	GO:0000956~nuclear-	LSM4, MRTO4	35.88	0.054	0.996	
ECT	transcribed mRNA catabolic					
	process					
GOTERM_BP_DIR	GO:0033962~cytoplasmic	LSM4, DDX6	35.88	0.054	0.996	
ECT	mRNA processing body					
	assembly					
GOTERM_BP_DIR	GO:0071425~hematopoietic	RUNX1, CTC1	33.317	0.058	0.994	
ECT	stem cell proliferation					
GOTERM_BP_DIR	GO:0051301~cell division	DSN1, CCNY, CCNF,	3.331	0.061	0.99	
ECT		ANXA11, CDK2				
GOTERM_BP_DIR	GO:0009165~nucleotide	PRPS1L1, PRPS1	31.096	0.062	0.983	
ECT	biosynthetic process					
GOTERM_CC_DIR	GO:0042470~melanosome	RAB9A, TMEM33,	7.217	0.063	0.708	
ECT		ANXA11				
GOTERM_CC_DIR	GO:0005856~cytoskeleton	ENAH, CTTN, NF2,	3.274	0.064	0.673	
ECT		RAB3IP, TPM3				
GOTERM_MF_DIR	GO:0005161~platelet-derived	PTPRJ, VEGFA	28.491	0.067	0.837	
ECT	growth factor receptor binding					
GOTERM_BP_DIR	GO:0050860~negative	PTPRJ, DUSP22	27.437	0.069	0.984	
ECT	regulation of T cell receptor					
	signaling pathway					
GOTERM_MF_DIR	GO:0044822~poly(A) RNA	PPAN-P2RY11,	1.892	0.075	0.828	
ECT	binding	RRP7A, XRCC6,				
		ANXA11, MTPAP,				
		LSM4, FTSJ3,				
		SAMD4A, MRTO4,				
		DDX6				
GOTERM_BP_DIR	GO:0009116~nucleoside	PRPS1L1, PRPS1	24.549	0.077	0.984	
ECT	metabolic process					
GOTERM_BP_DIR	GO:0051894~positive	PTPRJ, VEGFA	22.211	0.085	0.985	
ECT	regulation of focal adhesion					
	assembly					
GOTERM_BP_DIR	GO:0000027~ribosomal large	PPAN-P2RY11,	22.211	0.085	0.985	
ECT	subunit assembly	MRTO4				

27 th June						Gupta et al
GOTERM_CC_DIR	GO:0005770~late endosome	RAB9A, RAB22A,	5.975	0.087	0.757	
ECT		SDF4				
GOTERM_MF_DIR	GO:0019901~protein kinase	PTPRJ, FAM83C,	2.841	0.096	0.862	
ECT	binding	CCNY, CAMK2N2,				
		CD226				
GOTERM_BP_DIR	GO:0007422~peripheral	NFASC, UGT8	19.435	0.096	0.987	
ECT	nervous system development					

Appendix References

27th June

985

- 986 WHO. Guidelines for the treatment of malaria. 3rd ed. 2015. [cited 2020 08/06/2020];
- 987 Available from: https://www.who.int/malaria/publications/atoz/9789241549127/en/
- 988 Mayor A, Hafiz A, Bassat Q, Rovira-Vallbona E, Sanz S, Machevo S, et al. Association of
- severe malaria outcomes with platelet-mediated clumping and adhesion to a novel host receptor. 989
- 990 PLoS One. 2011 Apr 29;6(4):e19422.
- 991 Roberts DJ, Craig AG, Berendt AR, Pinches R, Nash G, Marsh K, et al. Rapid switching to 3. 992 multiple antigenic and adhesive phenotypes in malaria. Nature. 1992 Jun 25;357(6380):689-92.
- 993 Magallon-Tejada A, Machevo S, Cistero P, Lavstsen T, Aide P, Rubio M, et al.
- 994 Cytoadhesion to gC1qR through Plasmodium falciparum Erythrocyte Membrane Protein 1 in
- 995 Severe Malaria. PLoS pathogens. 2016 Nov;12(11):e1006011.
- 996 Kirschner MB, Edelman JJ, Kao SC, Vallely MP, van Zandwijk N, Reid G. The Impact of 5. 997 Hemolysis on Cell-Free microRNA Biomarkers. Frontiers in genetics. 2013;4:94.
- 998 Wang J, Chen J, Chang P, LeBlanc A, Li D, Abbruzzesse JL, et al. MicroRNAs in plasma of 999 pancreatic ductal adenocarcinoma patients as novel blood-based biomarkers of disease. Cancer .000 prevention research. 2009 Sep;2(9):807-13.
- Rubio M, Bustamante M, Hernandez-Ferrer C, Fernandez-Orth D, Pantano L, Sarria Y, et al. .001 7.
- .002 Circulating miRNAs, isomiRs and small RNA clusters in human plasma and breast milk. PLoS .003 One. 2018:13(3):e0193527.
- .004 Griffiths-Jones S, Grocock RJ, van Dongen S, Bateman A, Enright AJ. miRBase:
- .005 microRNA sequences, targets and gene nomenclature. Nucleic acids research. 2006 Jan .006 1:34(Database issue):D140-4.
- Pantano L, Estivill X, Marti E. SeqBuster, a bioinformatic tool for the processing and .007
- .008 analysis of small RNAs datasets, reveals ubiquitous miRNA modifications in human embryonic
- .009 cells. Nucleic acids research. 2010 Mar;38(5):e34.
- .010 Pantano L. Estivill X. Marti E. A non-biased framework for the annotation and classification
- of the non-miRNA small RNA transcriptome. Bioinformatics. 2011 Nov 15;27(22):3202-3. .011
- Love MI, Huber W, Anders S. Moderated estimation of fold change and dispersion for .012
- .013 RNA-seq data with DESeq2. Genome biology. 2014;15(12):550.
- Marabita F, de Candia P, Torri A, Tegner J, Abrignani S, Rossi RL. Normalization of .014
- circulating microRNA expression data obtained by quantitative real-time RT-PCR. Briefings in .015
- .016 bioinformatics. 2016 Mar;17(2):204-12.
- .017 Yeri A, Courtright A, Reiman R, Carlson E, Beecroft T, Janss A, et al. Total Extracellular 13.
- Small RNA Profiles from Plasma, Saliva, and Urine of Healthy Subjects. Scientific reports. 2017 .018
- .019 Mar 17;7:44061.
- Andersen CL, Jensen JL, Orntoft TF. Normalization of real-time quantitative reverse .020
- transcription-PCR data: a model-based variance estimation approach to identify genes suited for .021
- .022 normalization, applied to bladder and colon cancer data sets. Cancer research. 2004 Aug
- .023 1;64(15):5245-50.
- .024 Paraskevopoulou MD, Georgakilas G, Kostoulas N, Vlachos IS, Vergoulis T, Reczko M, et
- .025 al. DIANA-microT web server v5.0: service integration into miRNA functional analysis workflows.
- Nucleic acids research. 2013 Jul;41(Web Server issue):W169-73. .026
- Tokar T, Pastrello C, Rossos AEM, Abovsky M, Hauschild AC, Tsay M, et al. mirDIP 4.1-.027 16.
- .028 integrative database of human microRNA target predictions. Nucleic acids research. 2018 Jan
- .029 4;46(D1):D360-D70.
- Andres-Leon E, Gonzalez Pena D, Gomez-Lopez G, Pisano DG. miRGate: a curated .030 17.
- .031 database of human, mouse and rat miRNA-mRNA targets. Database: the journal of biological
- .032 databases and curation. 2015;2015:bav035.
- Chou CH, Shrestha S, Yang CD, Chang NW, Lin YL, Liao KW, et al. miRTarBase update .033
- .034 2018: a resource for experimentally validated microRNA-target interactions. Nucleic acids research.
- .035 2018 Jan 4;46(D1):D296-D302.

27th June Gupta et al

Benjamini Y, Drai D, Elmer G, Kafkafi N, Golani I. Controlling the false discovery rate in .036 19. behavior genetics research. Behavioural brain research. 2001 Nov 1;125(1-2):279-84. .037

.038